Patent Grant
7498159
The present invention relates to an alpha amylase, which is derived from a strain of Aspergillus kawachi. Further, the invention relates to the heterologous expression of an alpha amylase in filamentous fungal host cells, such as Aspergillus cells (e.g. Aspergillus niger) and to enzyme compositions comprising the alpha amylase.
Glucoamylases, and including glucoamylases having granular starch hydrolyzing (GSH) activity are important industrial enzymes used for producing products such as organic acids (e.g. lactic acids), amino acids (e.g. glutamic acids), sugar sweetener products (e.g. glucose and high fructose corn syrup), alcohols (e.g. ethanol) and other compounds from starch substrates derived from grains and cereals. In addition, during microbial fermentations, and particularly during simultaneous saccharification and fermentation (SSF), it would be of benefit to reduce the amount of residual starch in the fermentation when granular starch substrates are used as a carbon feed. The present invention answers this need by providing an alpha amylase, such as an acid-stable alpha amylase (asAA) having granular starch hydrolyzing (GSH) activity, which may be used in combination with a glucoamylase to enhance starch hydrolysis and alcohol production.
Some benefits of the present invention over prior art compositions and methods include one or more of the following: a) reduction of thermal energy use during starch hydrolysis and/or end-product production; b) reduction in the requirement of high enzyme dosage; c) utilization of a continuous release of glucose from starch to feed yeast; d) maintenance of a relatively low glucose level in the fermenter, which may reduce the high risk of microbial contamination and which may remove the catabolite repression of yeast due to high concentration of free glucose; e) reduction in formation of browning reaction products; f) reduction or removal of calcium addition, which may be required during the prior art jet cooking process; g) reduction in water utilization during the fermentation process; h) use of higher solids content in the fermentation, which may result in higher end-product formation and reduced energy costs; i) reduced levels of production of certain by-products, such as glycerol; and/or j) decreased residual starch content and increased protein content of distillers dry grains plus solubles.
In one aspect, the invention relates to a fungal host cell comprising a heterologous polynucleotide that encodes an acid-stable alpha amylase (asAA) having granular starch hydrolyzing (GSH) activity, said alpha amylase having at least 90% sequence identity to the sequence of SEQ ID NO: 3. In some embodiments, the heterologous polynucleotide will encode an asAA having GSH activity with at least 95% sequence identity to the sequence of SEQ ID NO: 3. In some embodiments, the fungal host cell is a Trichoderma cell, such as a T. reesei cell. In other embodiments, the fungal host cell is an Aspergillus cell, such as an A. niger.
In a second aspect, the invention relates to an asAA having GSH activity comprising an amino acid sequence having at least 90% sequence identity with SEQ ID NO: 3. In some embodiments of this aspect, the asAA having GSH activity will be a truncated asAA. In some embodiments, the truncated asAA comprises a sequence of SEQ ID NO: 9 or a sequence having at least 97% sequence identity thereto.
In a third aspect, the invention relates to an enzyme composition which comprises an acid-stable alpha amylase (asAA) having granular starch hydrolyzing (GSH) activity, wherein the asAA has at least 90% sequence identity to the sequence of SEQ ID NO: 3. In some embodiments, the enzyme composition comprises a truncated asAA enzyme, said enzyme having at least 97% sequence identity with SEQ ID NO: 9. In some embodiments, the asAA will be obtained from the expression of a heterologous polynucleotide in a fungal host cell. In further embodiments, the fungal host cell will be a Trichoderma or Aspergillus host cell. In other embodiments, the composition will further include a glucoamylase enzyme. In some embodiments, the glucoamylase enzyme will be obtained from a strain of Aspergillus or Rhizopus. In other embodiments, the glucoamylase will be a glucoamylase having GSH activity and will be obtained from a strain of Aspergillus, Trichoderma, Rhizopus or Humicola. In other embodiments, both the asAA and the glucoamylase will be expressed in the same fungal host having a heterologous polynucleotide, which expresses an asAA having GSH activity and the glucoamylase. In other embodiments, the invention relates to a method of hydrolyzing starch, such as granular starch using the enzyme composition of this aspect.
In a fourth aspect, the invention relates to a recombinant Aspergillus strain comprising DNA encoding a glucoamylase and DNA encoding a heterologous alpha amylase, said alpha amylase having at least 90% sequence identity to SEQ ID NO: 3 or SEQ ID NO: 4, wherein both the glucoamylase and the heterologous alpha amylase are expressed and secreted by the Aspergillus strain.
In a fifth aspect, the invention relates to a method for producing an alpha amylase and a glucoamylase in a filamentous fungal host cell comprising transforming an Aspergillus host cell which produces a glucoamylase with a DNA construct including a promoter having transcriptional activity in the Aspergillus host cell operably linked to a polynucleotide encoding an alpha amylase having at least 85% sequence identity to SEQ ID NO: 3 or SEQ ID NO: 4, cultivating the transformed Aspergillus host cell in a suitable culture medium to allow expression of said alpha amylase and the glucoamylase, and producing the alpha amylase and glucoamylase. In one embodiment, the method further comprises recovering the produced alpha amylase and glucoamylase.
In a sixth aspect, the invention relates to a method of producing an alpha amylase in an Aspergillus cell which comprises, culturing an Aspergillus cell which is capable of expressing a heterologous alpha amylase polypeptide having at least 90% sequence identity to SEQ ID NO: 3 or SEQ ID NO: 4 under conditions suitable for the expression and production of the heterologous alpha amylase and producing the heterologous alpha amylase.
In a seventh aspect, the invention relates to a method for producing a heterologous acid stable alpha amylase and a glucoamylase in a filamentous fungal host cell comprising co-expressing a glucoamylase and an alpha amylase in a filamentous host by transforming the filamentous fungal cell with a DNA construct comprising a promoter having transcriptional activity in the host cell operably linked to a polynucleotide encoding an alpha amylase having at least 90% sequence identity to SEQ ID NO: 3, wherein said host cell further expresses and produces a glucoamylase, cultivating the transformed host cell in a suitable culture medium to allow expression of the alpha amylase and glucoamylase, and producing the alpha amylase and the glucoamylase.
In an eighth aspect, the invention relates to a method of hydrolyzing starch, such as granular starch which comprises contacting a substrate containing starch with an enzyme composition comprising the alpha amylase and glucoamylase produced according to the methods encompassed by the invention. In one embodiment contacting includes contacting the substrate with a culture medium that includes the Aspergillus cells producing the glucoamylase and alpha amylase. In another embodiment, contacting includes contacting the substrate with glucoamylase and alpha amylase which has been recovered from a culture of Aspergillus cells that produces the glucoamylase and alpha amylase. In further embodiments, the alpha amylase has at least 85% sequence identity to the sequence of SEQ ID NO: 3 or SEQ ID NO: 4.
In some aspects, the present invention relies on routine techniques and methods used in the field of genetic engineering and molecular biology. The following resources include descriptions of general methodology useful in accordance with the invention: Sambrook et al., M
Unless defined otherwise herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton, et al., D
Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described.
The invention will now be described in detail by way of reference only using the following definitions and examples. All patents and publications, including all sequences disclosed within such patents and publications, referred to herein are expressly incorporated by reference.
Numeric ranges are inclusive of the numbers defining the range.
Unless otherwise indicated, nucleic acids are written left to right in 5′ to 3′ orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively.
The headings provided herein are not limitations of the various aspects or embodiments of the invention which can be had by reference to the specification as a whole.
DEFINITIONS
As used herein the term “starch” refers to any material comprised of the complex polysaccharide carbohydrates of plants, comprised of amylose and amylopectin with the formula (C6H10O5)x, wherein X can be any number. In particular, the term refers to any plant-based material including but not limited to grains, grasses, tubers and roots and more specifically wheat, barley, corn, rye, rice, sorghum, brans, cassava, millet, potato, sweet potato, and tapioca.
As used herein the term “granular starch” refers to raw (uncooked) starch, e.g., starch that has not been subject to gelatinization.
As used herein the terms “granular starch hydrolyzing (GSH) enzyme” and “having granular starch hydrolyzing (GSH) activity” refer to enzymes, which have the ability to hydrolyze starch in granular form.
As used herein the term “alpha-amylase (e.g., E.C. class 3.2.1.1)” refers to enzymes that catalyze the hydrolysis of alpha-1,4-glucosidic linkages. These enzymes have also been described as those effecting the exo or endohydrolysis of 1,4-α-D-glucosidic linkages in polysaccharides containing 1,4-α-linked D-glucose units. Another term used to describe these enzymes is “glycogenase”. Exemplary enzymes include alpha-1,4-glucan 4-glucanohydrase glucanohydrolase.
As used herein the term “acid-stable alpha amylase (“asAA”) refers to an alpha amylase that has activity in the pH range of pH 3.0 to 7.0 and also in the pH range of 3.5 to 6.5.
As used herein the term “truncated” such as “truncated alpha amylase” refers to an enzyme, wherein at least part of the starch binding domain has been eliminated, but the functional portion retains a biological function, such as a catalytic function.
As used herein the term “starch binding domain (SBD)” refers to an amino acid sequence that binds preferentially to a starch (polysaccharide) substrate.
As used herein the term “linker” refers to a short amino acid sequence generally having between 3 and 40 amino acid residues which covalently bind an amino acid sequence comprising a starch binding domain with an amino acid sequence comprising a catalytic domain.
As used herein the term “catalytic domain” refers to a structural region of a polypeptide which is distinct from the SBD and which contains the active site for substrate hydrolysis.
As used herein the term “glucoamylase” refers to the amyloglucosidase class of enzymes (e.g., EC.3.2.1.3, glucoamylase, 1,4-alpha-D-glucan glucohydrolase). These are exo-acting enzymes, which release glucosyl residues from the non-reducing ends of amylose and amylopectin molecules. The enzyme also hydrolyzes alpha-1,6 and alpha-1,3 linkages although at much slower rate than alpha-1,4 linkages.
As used herein the term “glycosylation” refers to the post-transcriptional modification of a protein by the addition of carbohydrate moieties, wherein the carbohydrate is either N-linked or O-linked resulting in a glycoprotein. An N-linked carbohydrate moiety of a glycoprotein is attached by a glycosidic bond to the β-amide nitrogen of an asparagine residue. An O-linked carbohydrate is attached by a glycosidic bond to a protein through the hydroxy group of a serine or a threonine residue.
As used herein the term “recombinant” when used in reference to a cell, nucleic acid, protein or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.
As used herein the terms “protein” and “polypeptide” are used interchangeably herein. The conventional one-letter or three-letter code for amino acid residues is used herein.
As used herein the term “signal sequence” means a sequence of amino acids bound to the N-terminal portion of a protein, which facilitates the secretion of the mature form of the protein outside the cell. The definition of a signal sequence is a functional one. The mature form of the extracellular protein lacks the signal sequence, which is cleaved off during the secretion process.
As used herein the term “native acid-stable alpha amylase (n-asAA)” refers to an acid-stable alpha amylase (asAA) produced from the endogenous expression of the asAA. For example, the term “n-asaA” means the endogenous expression of an acid-stable alpha amylase (e.g., SEQ ID NO: 3) from an Aspergillus kawachi.
As used herein the terms “recombinant acid-stable alpha amylase (r-asAA)”, “recombinantly expressed asAA” and “recombinantly produced asAA” refer to a mature asAA protein sequence that is produced in a host cell from the expression of a heterologous polynucleotide. For example, the term “r-asaA” means the Aspergillus kawachi acid-stable alpha amylase (e.g., SEQ ID NO: 3) is expressed and produced in a host in which a polynucleotide encoding the asaA has been introduced.
As used herein the term “gene” refers to a DNA segment that is involved in producing a polypeptide and includes regions preceding and following the coding regions as well as intervening sequences (introns) between individual coding segments (exons).
As used herein the term “nucleic acid” encompasses DNA, RNA, single stranded or double stranded and chemical modifications thereof.
The terms “nucleic acid” and “polynucleotide” may be used interchangeably herein.
As used herein the term “vector” refers to a polynucleotide sequence designed to introduce nucleic acids into one or more cell types. Vectors include cloning vectors, expression vectors, shuttle vectors, plasmids, phage particles, cassettes and the like.
As used herein the term an “expression vector” means a DNA construct comprising a DNA sequence which is operably linked to a suitable control sequence capable of effecting expression of the DNA in a suitable host. Such control sequences may include a promoter to effect transcription, an optional operator sequence to control transcription, a sequence encoding suitable ribosome binding sites on the mRNA, enhancers and sequences which control termination of transcription and translation.
As used herein the term “promoter” means a regulatory sequence that is involved in binding RNA polymerase to initiate transcription of a gene. The promoter may be an inducible promoter or a constitutive promoter.
As used herein the phrase “under transcriptional control” indicates that transcription of a polynucleotide sequence, usually a DNA sequence, depends on its being operably linked to an element which contributes to the initiation of, or promotes transcription.
As used herein the phrase “under translational control” is a term well understood in the art that indicates a regulatory process that occurs after mRNA has been formed.
As used herein when describing proteins and genes that encode them, the term for the gene is generally italicized, (e.g., the gene that encodes asaA (A. kawachi asAA) may be denoted as asaA). The term for the protein is generally not italicized and the first letter is generally capitalized, (e.g., the protein encoded by the asaA gene may be denoted as AsaA or asaA).
As used herein the term “derived” encompasses the terms “originated from”, “obtained” or “obtainable from”, and “isolated from” and as used herein means that the polypeptide encoded by the nucleotide sequence is produced from a cell in which the nucleotide is naturally present or in which the nucleotide sequence has been inserted.
As used herein the term “operably linked” refers to juxtaposition wherein the elements are in an arrangement allowing them to be functionally related. For example, a promoter is operably linked to a coding sequence if it controls the transcription of the sequence.
As used herein the term “selective marker” refers to a gene capable of expression in a host that allows for ease of selection of those hosts containing an introduced nucleic acid or vector.
A polynucleotide or a polypeptide having a certain percent (e.g. 80%, 85%, 90%, 95%, or 99%) of sequence identity with another sequence means that, when aligned, that percentage of bases or amino acid residues are the same in comparing the two sequences. This alignment and the percent homology or identity can be determined using any suitable software program known in the art, for example those described in C
One skilled in the art will recognize that sequences encompassed by the invention are also defined by the ability to hybridize under stringent hybridization conditions with the exemplified asaA sequence (e.g., SEQ ID NO:1). A nucleic acid is hybridizable to another nucleic acid sequence when a single stranded form of the nucleic acid can anneal to the other nucleic acid under appropriate conditions of temperature and solution ionic strength. Hybridization and washing conditions are well known in the art (See, e.g., Sambrook (1989) supra, particularly chapters 9 and 11). In some embodiments, stringent conditions correspond to a Tm of 65° C. and 0.1×SSC, 0.1% SDS.
As used herein “host strain” or “host cell” means a suitable host for an expression vector or DNA construct comprising a polynucleotide encoding an alpha amylase according to the invention. Specifically, host strains are preferably filamentous fungal cells. The host cell may be a wild type filamentous fungal host cell or a genetically modified host cell. The term host cell or host strain means both the cells and protoplasts created from the cells of a filamentous fungal strain.
The term “filamentous fungi” refers to all filamentous forms of the subdivision Eumycotina (See, Alexopoulos, C. J. (1962), I
As used herein, the term “Trichoderma” or “Trichoderma sp.” refer to any fungal genus previously or currently classified as Trichoderma.
As used herein the term “culturing” refers to growing a population of microbial cells under suitable conditions in a liquid or solid medium. In one embodiment, culturing refers to fermentative bioconversion of a starch substrate, such as a substrate comprising granular starch, to an end-product (typically in a vessel or reactor). Fermentation is the enzymatic and anaerobic breakdown of organic substances by microorganisms to produce simpler organic compounds. While fermentation occurs under anaerobic conditions it is not intended that the term be solely limited to strict anaerobic conditions, as fermentation also occurs in the presence of oxygen.
As used herein the phrase “simultaneous saccharification and fermentation (SSF)” refers to a process in the production of end-products in which a microbial organism, such as an ethanol producing microorganism and at least one enzyme such as an alpha amylase are in the same process step. In one embodiment of the present invention, SSF refers to the contemporaneous hydrolysis of granular starch substrates to saccharides including glucose and the fermentation of the saccharides into alcohol in the same reactor vessel.
As used herein the term “contacting” refers to the placing of the respective enzyme(s) in sufficiently close proximity to the respective substrate to enable the enzyme(s) to convert the substrate to the end-product. Those skilled in the art will recognize that mixing solutions of the enzyme with the respective substrates can effect contacting.
As used herein the term “enzymatic conversion” in general refers to the modification of a substrate by enzyme action. The term as used herein also refers to the modification of a granular starch substrate by the action of an enzyme.
As used herein the term “saccharification” refers to enzymatic conversion of starch to glucose.
As used herein the term “gelatinization” means solubilization of a starch molecule by cooking to form a viscous suspension.
As used herein the term “gelatinization temperature” refers to the temperature at which gelatinization of a starch begins. The exact temperature of gelatinization depends on the specific starch and may vary depending on factors such as, plant species and environmental and growth conditions.
As used herein the phrase “below the gelatinization temperature” refers to a temperature less than the temperature that starts gelatinization.
As used herein the term “liquefaction” refers to the stage in starch conversion in which gelatinized starch is hydrolyzed to give low molecular weight soluble dextrins.
As used herein the term “degree of polymerization (DP)” refers to the number (n) of anhydroglucopyranose units in a given saccharide. Examples of DP1 are the monosaccharides, such as glucose and fructose. Examples of DP2 are the disaccharides, such as maltose and sucrose. A DP>3 denotes polymers with a degree of polymerization of greater than 3.
As used herein the term “end-product” or “desired end-product” refers to any carbon-source derived molecule product which is enzymatically converted from the starch substrate, such as a starch substrate comprising granular starch.
As used herein the term “dry solids content (ds)” refers to the total solids of a slurry in % on a dry weight basis.
As used herein the term “slurry” refers to an aqueous mixture containing insoluble solids.
As used herein the term “soluble starch hydrolyzate” refers to soluble products resulting from starch hydrolysis, which may comprise mono-, di-, and oligosaccharides (e.g. glucose, maltose and higher sugars).
As used herein the term “residual starch” refers to the remaining starch (soluble or insoluble) left in a composition after fermentation of a starch containing substrate.
As used herein the terms “distillers dried grain (DDG)” and “distillers dried grain with solubles (DDGS)” refer to useful co-products of grain fermentation.
As used herein the term “mash” refers to a mixture of a fermentable carbon source (carbohydrate) in water used to produce a fermented product, such as an alcohol. In some embodiments, the term “beer”, “mash” and “fermentation broth” may be used interchangeability.
As used herein “ethanologenic microorganism” refers to a microorganism with the ability to convert a sugar or oligosaccharide to ethanol. The ethanologenic microorganisms are ethanologenic by virtue of their ability to express one or more enzymes that individually or together convert sugar to ethanol.
As used herein the term “ethanol producer” or ethanol producing microorganism” refers to any organism or cell that is capable of producing ethanol from a hexose or pentose. Generally, ethanol-producing cells contain an alcohol dehydrogenase and a pyruvate decarboxylase. Examples of ethanol producing microorganisms include fungal microorganisms such as yeast. A preferred yeast includes strains of Saccharomyces, particularly, S. cerevisiae.
As used herein the term “heterologous” with reference to a polynucleotide or protein refers to a polynucleotide or protein that does not naturally occur in a host cell. It is intended that the term encompass proteins that are encoded by naturally occurring genes, mutated genes, and/or synthetic genes.
As used herein the term “endogenous” with reference to a polynucleotide or protein refers to a polynucleotide or protein that occurs naturally in the host cell.
As used herein the terms “recovered”, “isolated”, and “separated” as used herein refer to a compound, protein, cell, nucleic acid or amino acid that is removed from at least one component with which it is naturally associated.
As used herein, the terms “transformed”, “stably transformed” and “transgenic” used in reference to a cell means the cell has a non-native (e.g., heterologous) nucleic acid sequence integrated into its genome or as an episomal plasmid that is maintained through multiple generations.
As used herein, the term “expression” refers to the process by which a polypeptide is produced based on the nucleic acid sequence of a gene. The process includes both transcription and translation.
As used herein the term “overproducing glucoamylase strain” refers to a filamentous fungal host cell that expresses and produces glucoamylase and further secretes the glucoamylase from the cell such that the secreted glucoamylase comprises at least 40% of the total amount of secreted protein.
The term “introduced” in the context of inserting a nucleic acid sequence into a cell, means “transfection”, or “transformation” or “transduction” and includes reference to the incorporation of a nucleic acid sequence into a eukaryotic or prokaryotic cell wherein the nucleic acid sequence may be incorporated into the genome of the cell (e.g., chromosome, plasmid, plastid, or mitochondrial DNA), converted into an autonomous replicon, or transiently expressed (e.g., transfected mRNA).
As used herein the term “specific activity” means an enzyme unit defined as the number of moles of substrate converted to product by an enzyme preparation per unit time under specific conditions. Specific activity is expressed as units (U)/mg of protein.
As used herein the term “enzyme unit” refers to the amount of enzyme that produces a given amount of product per given amount of time under assay conditions. In some embodiments, an enzyme unit refers to the amount of enzyme that produces 1 micromole of product per minute under the specified conditions of the assay. For example, in one embodiment, the term “glucoamylase activity unit” (GAU) is defined as the amount of enzyme required to produce 1 g of glucose per hour from soluble starch substrate (4% ds) under assay conditions of 60° C. and pH 4.2.
In another embodiment, a granular starch hydrolyzing enzyme unit (GSHE U) is defined as being the amount of GSHE required to produce 1 mg of glucose per minute from granular starch under assay conditions of, for example 25° C. at pH 5.0. In a preferred embodiment, a GSHE U is defined as being the amount of a GSHE required to produce 1 mg glucose/min from a granular starch substrate at 50° C. at pH 4.5.
The term “yield” refers to the amount of end-product or desired end-products produced using the methods of the present invention. In some preferred embodiments, the yield is greater than that produced using methods known in the art. In some embodiments, the term refers to the volume of the end product and in other embodiment the term refers to the concentration of the end product.
“ATCC” refers to American Type Culture Collection located at Manassas, Va. 20108 (ATCC; <www.atcc.org>).
“NRRL” refers to the Agricultural Research Service Culture Collection, National Center for Agricultural Utilization Research (and previously known as USDA Northern Regional Research Laboratory), Peoria, Ill.
“A”, “an” and “the” include plural references unless the context clearly dictates otherwise.
As used herein the phrase “at least” when used in combination with a list of values or terms is meant to apply to each value or term in the list. For example, the phrase “at least 85%, 90%, 95% and 99% sequence identity” is used to denote at least 85%, at least 90%, at least 95% and/or at least 99% sequence identity.
As used herein the term “comprising” and its cognates are used in their inclusive sense; that is, equivalent to the term “including” and its corresponding cognates.
Alpha Amylases:
In one embodiment of the invention, an alpha amylase, such as an acid stable alpha amylase (asAA) having GSH activity, is obtained from a strain of Aspergillus, e.g., A. oryzae, A. kawachi, A. niger, and A. awamori. In certain embodiments, the alpha amylase is an acid stable alpha amylase that is obtained from a strain of Aspergillus kawachi.
In some embodiments, the alpha amylase (e.g., an asAA having GSH activity) comprises an amino acid sequence having at least 80%, 85%, 90%, 93%, 94%, 95%, 96%, 97%, 98% and 99% sequence identity with the amino acid sequence set forth in SEQ ID NO: 3. In another embodiment, the asAA comprises an amino acid sequence having at least 90% sequence identity with SEQ ID NO: 3. In a further embodiment, the asAA comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 3. The asAA may also comprise an amino acid sequence having at least 98% sequence identity with SEQ ID NO: 3. In a further embodiment, the asAA comprises the amino acid sequence of SEQ ID NO: 3. In some embodiments, SEQ ID NO: 3 or a sequence having at least 85% identity thereto is considered an intact asAA. More generally, an intact alpha amylase is an alpha amylase comprising a catalytic domain, linker region and a starch binding domain.
In some embodiments, the alpha amylase will include a catalytic domain having at least 96%, 97%, 98% and 99% sequence identity with SEQ ID NO: 9. In other embodiments, the alpha amylase will include a SBD having at least 70%, 75%, 80%, 85%, 90%, 93%, 95%, 96%, 97% 98% and 99% sequence identity with the SBD of SEQ ID NO: 10.
In further embodiments, the alpha amylase will comprise at least 97%, 98%, and 99% sequence identity with SEQ ID NO: 9; at least 96%, 97%, 98% and 99% sequence identity with SEQ ID NO: 8; and at least 95%, 96%, 97%, 98% and 99% sequence identity with SEQ ID NO: 10. In certain embodiments, the catalytic domain and the SBD are obtained from an alpha amylase of an Aspergillus kawachi strain.
In other embodiments, the alpha amylase is a truncated enzyme. In some embodiments the truncated alpha amylase will include at least 60%, 65%, 70%, 75%, 80%, 83%, 85%, 88%, 90%, 93%, 95%, 96%, 97%, 98% and 99% of the amino acid sequence of SEQ ID NO: 3 and in other embodiments a truncated alpha amylase will encompass at least 60%, 65%, 70%, 75%, 80%, 83%, 85%, 88%, 90%, 93%, 95%, 96%, 97%, 98% and 99% of a sequence having at least 90%, 95%, 98% and 99% sequence identity with SEQ ID NO: 3. The enzyme may be truncated at the carboxy terminus end of the polypeptide. In some embodiments the truncated alpha amylase includes at least 430, 440, 450, 460 and 470 amino acids of SEQ ID NO: 3 or a sequence having at least 90% sequence identity thereto.
In some embodiments, the truncated alpha amylase will include at least 90%, 95%, 96%, 97%, 98% and 99% of the catalytic domain of SEQ ID NO: 9 or a sequence having at least 97%, 98% and 99% sequence identity thereto.
In some embodiments, the truncated alpha amylase will include the catalytic domain of SEQ ID NO: 9 or a sequence having at least 96%, 97%, 98% and 99% sequence identity thereto and a linker having at least 90%, 95%, 96%, 97%, 98% and 99% sequence identity to SEQ ID NO: 8. In some embodiments the truncated enzyme will include a catalytic domain having at least 97% sequence identity with SEQ ID NO: 9 and a linker having at least 95% sequence identity with SEQ ID NO: 8. In some embodiments, the truncated enzyme will include a catalytic domain having at least 96%, 97%, 98% and 99% sequence identity to SEQ ID NO: 9 and at least about 5, 10, 20, 25, 30 and 35 amino acids located downstream of the catalytic domain. In other embodiments, the truncated enzyme will include a catalytic domain and a linker as defined above and further a portion of the SBD having at least 70%, 75%, 80%, 85%, 90%, 93%, 95%, 96%, 97%, 98% and 99% sequence identity to the sequence of SEQ ID NO: 10. The portion of the SBD will include at least about 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100 amino acids located downstream of the linker.
In other embodiments, the asAA comprising the amino acid sequence of SEQ ID NO: 3 or an amino acid sequence having at least 95% sequence identity with SEQ ID NO: 3 is encoded by a polynucleotide having at least 70%, 80%, 85%, 90%, 93%, 95%, 96%, 97%, 98% and 99% sequence identity to the sequence of SEQ ID NO: 1. In one embodiment, the nucleic acid sequence encoding the asAA of SEQ ID NO: 3 (AsaA) is the nucleic acid sequence of SEQ ID NO: 1.
Recombinantly Expressed Enzymes and Host Cells:
In some embodiments of the invention, microorganisms are genetically engineered to express heterologous alpha amylases, such as an alpha amylase (e.g. an asAA having GSH activity) and having at least 80%, 85%, 90%, 93%, 94%, 95%, 96%, 97%, 98% and 99% sequence identity with SE ID NO: 3. Microorganisms may also be engineered to express heterologous glucoamylases. Preferred host cells are filamentous fungal cells. In some embodiments, the filamentous fungal host is a strain of an Aspergillus sp., a Trichoderma sp., a Fusarium sp. and a Penicillium sp.
Some preferred fungal host cells include A. nidulans, A. awamori, A. oryzae, A. aculeatus, A. niger, A. japonicus, T. reesei, T. viride, F. oxysporum, and F. solani. Aspergillus strains are disclosed in Ward et al. (1993) Appl. Microbiol. Biotechnol. 39:738-743 and Goedegebuur et al., (2002) Curr Gene 41:89-98. In some preferred embodiments, the host is a strain of Trichoderma, and particularly a strain of T. reesei. Strains of T. reesei are known and nonlimiting examples include ATCC No. 13631, ATCC No. 26921, ATCC No. 56764, ATCC No. 56765, ATCC No. 56767 and NRRL 15709. In some preferred embodiments, the host strain is a derivative of RL-P37. RL-P37 is disclosed in Sheir-Neiss et al. (1984) Appl. Microbiol. Biotechnology 20:46-53.
In other preferred embodiments, the host is a strain of Aspergillus. Useful Aspergillus host strains include without limitation A. nidulans (Yelton et al., (1984) Proc. Natl. Acad. Sci. USA 81: 1470-1474; Mullaney et al., (1985) Mol. Gen. Genet. 199:37-45; and Johnston et al., (1985) EMBO J. 4: 1307-1311); A. niger (Kelly et al., (1985) EMBO J. 4:475-479), A. awamori (NRRL 3112, UVK143f (U.S. Pat. No. 5,364,770), ATCC No. 22342, ATCC No. 44733, ATCC No. 14331 and ATCC No. 11490) and A. oryzae (ATCC No. 11490) and derivative strains thereof. In some embodiments, the Aspergillus strain is a pyrG mutant strain and consequentially requires uridine for growth. In some embodiments, the Aspergillus host strain expresses and produces endogenous alpha amylases. In some embodiments, the Aspergillus host strain is a strain that normally expresses and produces endogenous glucoamylases.
The term co-expression refers to the expression of a polynucleotide which has been introduced into a host cell which encodes an alpha amylase having at least 80% sequence identity to SEQ ID NO: 3, wherein the host cell or strain also expresses and produces a glucoamylase, such as an endogenous glucoamylase.
In some embodiments, the Aspergillus strain includes a wild-type glucoamylase although the strain may have been genetically engineered. Numerous Aspergillus strains express and produce glucoamylases. In particular, the gene encoding glucoamylase is highly expressed in many strains of Aspergillus niger and Aspergillus awamori. Glucoamylases are secreted enzymes so that the mature form of the glucoamylase is released to the external medium. Two forms of mature glucoamylases have been recognized in culture medium. These include GA I which is a full length form of glucoamylase comprising 616 amino acids and GA II which is a natural proteolytic fragment comprising 512 amino acids. GA II lacks a starch binding domain. See specifically, Boel et al., (1984) EMBO J. 3:1097-1102; WO 92/00381 and WO 00/04136 specifically incorporated by reference herein. Also reference is made to SEQ ID NO: 24 of WO 05/045018 and SEQ ID NO: 2 and SEQ ID NO: 13 of U.S. Pat. No. 6,352,851, incorporated herein by reference. The details of glucoamylase structure have been reviewed by Libby et al., (1994) Protein Engineering 7:1109-114.
In some embodiments, a Trichoderma host cell or an Aspergillus host cell is genetically engineered to express an asAA having GSH activity characterized by an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% and 99% identity with SEQ ID NO: 3. In further embodiments, the asAA having GSH activity will comprise at least 97%, 98%, and 99% sequence identity with SEQ ID NO: 9; at least 96%, 97%, 98% and 99% sequence identity with SEQ ID NO: 8; and at least 95%, 96%, 97%, 98% and 99% sequence identity with SEQ ID NO: 10. In certain embodiments, the asAA is obtained from an alpha amylase of an Aspergillus kawachi strain.
In other embodiments, the invention comprises a nucleotide sequence which encodes the polypeptide of SEQ ID NO: 3, the polypeptide of SEQ ID NO: 9 or a truncated enzyme as defined herein. In some embodiments, the polynucleotide encoding an asAA will have a nucleic acid sequence of SEQ ID NO: 1 or a nucleic acid sequence having at least 70% sequence identity with SEQ ID NO: 1.
In some embodiments, the alpha amylase produced in a host cell engineered to include a heterologous polynucleotide encoding an asAA will have different, such as improved properties compared to the asAA produced by the endogenous expression of the asAA in a native host. These properties may include for example, increased enzyme activity, increased enzyme stability at lower pH levels or increased specific activity. In some embodiments, a heterologously produced asAA according to the invention may exhibit a maximum pH activity within a pH range of 3.0 to 6.0; also within a pH range of 3.0 to 5.0; within a pH range of 3.5 to 5.0 and also within a pH range of 3.5 to 4.5. In other embodiments, a heterologously produced asAA may have a greater stability or residual activity at a pH level of 3.0, 3.5, 4.0, 4.5 and/or 5.0 compared to a corresponding asAA endogenously produced from a native host under essentially the same conditions. In some embodiments, the level of enzyme stability for a heterologously produced asAA will be at least 0.5, 1.0, 2.0, or 2.5 times greater at a specific pH level compared to an endogenously expressed asAA at the same pH level. In some embodiments, these improved or different properties of the heterologously expressed asAA are particularly apparent in Trichoderma host cells. In some embodiments, the heterologously expressed asAA will be produced as an intact asAA having GSH activity which includes the catalytic domain, linker and SBD, for example the mature polypeptide illustrated in
In other embodiments, the host strain which is genetically engineered to express an asAA may also be genetically engineered to express a heterologous glucoamylase.
A host strain useful in the invention may have been previously manipulated through genetic engineering. In some embodiments, the genetically engineered host cell or strain may be a protease deficient strain. In other embodiments, expression of various native genes of the fungal host cell will have been reduced or inactivated. These genes include, for example genes encoding proteases and cellulolytic enzymes, such as endoglucanases (EG) and exocellobiohydrolases (CBH) (e.g. cbh1, cbh2, eg/1, eg/2 and eg/3). U.S. Pat. No. 5,650,322 discloses derivative strains of RL-P37 having deletions in the cbh1 gene and the cbh2 gene. Reference is also made to U.S. Pat. No. 5,472,864 and WO 05001036.
Vectors:
While the description below refers specifically to alpha amylases, such as asAA, one skilled in the art will readily understand that the same or similar methods apply to DNA constructs and vectors useful for introduction of a polynucleotide encoding GA into a host cell.
According to the invention, a DNA construct comprising nucleic acid encoding an asAA encompassed by the invention is constructed to transfer an asAA into a host cell. In one embodiment, the DNA construct is transferred to a host cell by an expression vector which comprises regulatory sequences operably linked to an asAA coding sequence.
The vector may be any vector which when introduced into a fungal host cell is integrated into the host cell genome and is replicated. Reference is made to the Fungal Genetics Stock Center Catalogue of Strains (FGSC, <www.fgsc.net>) for a list of vectors. Additional examples of suitable expression and/or integration vectors are provided in Sambrook et al., (1989) supra, Ausubel (1987) supra, van den Hondel et al. (1991) in Bennett and Lasure (Eds.) M
In some embodiments, nucleic acid encoding an asAA encompassed by the invention is operably linked to a suitable promoter, which shows transcriptional activity in the fungal host cell. The promoter may be derived from genes encoding proteins either homologous or heterologous to the host cell. Preferably, the promoter is useful in a Trichoderma host or Aspergillus host. Suitable nonlimiting examples of promoters include cbh1, cbh2, eg/1, eg/2, pepA, hfb1, hfb2, xyn1 and amy. In one embodiment, the promoter is one that is native to the host cell. For example, when T. reesei is the host, the promoter is a native T. reesei promoter. In a preferred embodiment, the promoter is T. reesei cbh1, which is an inducible promoter and has been deposited in GenBank under Accession No. D86235. An “inducible promoter” is a promoter that is active under environmental or developmental regulation. In another embodiment, the promoter is one that is heterologous to the fungal host cell.
Other examples of useful promoters are those derived from the genes encoding of A. awamori and A. niger glucoamylase (glaA) (Nunberg et al., (1984) Mol. Cell. Biol. 4:2306-2315, U.S. Pat. No. 5,364,770, U.S. Pat. No. 6,590,078 (e.g. example 3); Gwynne D., et al., (1987) BioTechnol. 5:713-710 and Boel et al., (1984) EMBO J. 3:1581-1585); Aspergillus niger alpha amylases, Aspergillus oryzae TAKA amylase, T. reesei xln1, T. reesei cellobiohydrolase 1 (EPA 137280A1), Rhizomucor miehei aspartic proteinase and A. niger neutral alpha amylase.
In some embodiments, the asAA coding sequence is operably linked to a signal sequence. The DNA encoding the signal sequence is preferably that which is naturally associated with the asAA gene to be expressed. Preferably, the signal sequence is encoded by an Aspergillus kawachi asaA gene that encodes an Ak-asaA. More preferably the signal sequence has at least 90%, 95%, 97%, and 99% sequence identity to the signal sequence of SEQ ID NO: 2. In additional embodiments, a signal sequence and a promoter sequence comprising a DNA construct or vector to be introduced into a fungal host cell are derived from the same source. For example, in some embodiments, the signal sequence is the cdh1 signal sequence which is operably linked to a cdh1 promoter.
In some embodiments, the expression vector also includes a termination sequence. In one embodiment, the termination sequence and the promoter sequence are derived from the same source. In another embodiment, the termination sequence is homologous to the host cell. A particularly suitable terminator sequence is cbh1 derived from a Trichoderma strain and particularly T. reesei. Other useful fungal terminators include the terminator from A. niger, A. tubingensis, or A. awamori glucoamylase genes (Nunberg et al. (1984) supra, and Boel et al., (1984) supra).
In some embodiments, an expression vector includes a selectable marker. Examples of preferred selectable markers include but are not limited to ones that confer antimicrobial resistance (e.g., hygromycin, bleomycin, chloroamphenicol and phleomycin). Gene that confer metabolic advantage, such as nutritional selective markers, also find use in the present invention including those markers known in the art as amdS argB and pyr4. Markers useful in vector systems for transformation of Trichoderma are known in the art (See, e.g., Finkelstein, chapter 6 in B
An expression vector comprising a DNA construct with a polynucleotide encoding an alpha amylase may be any vector which is capable of replicating autonomously in a given fungal host organism or of integrating into the DNA of the host. In some embodiments, the expression vector is a plasmid. In preferred embodiments, two types of expression vectors for obtaining expression of genes are contemplated.
The first expression vector comprises DNA sequences in which the promoter, asAA coding region, and terminator all originate from the gene to be expressed. In some embodiments, gene truncation is obtained by deleting undesired DNA sequences (e.g., DNA encoding unwanted domains) to leave the domain to be expressed under control of its own transcriptional and translational regulatory sequences.
The second type of expression vector is preassembled and contains sequences required for high-level transcription and a selectable marker.
In some embodiments, the coding region for an asAA gene or part thereof is inserted into this general-purpose expression vector such that it is under the transcriptional control of the expression construct promoter and terminator sequences. In some embodiments, genes or part thereof are inserted downstream of the strong cbh1 promoter.
Methods used to ligate the DNA construct comprising a polynucleotide encoding an asAA, a promoter, a terminator and other sequences and to insert them into a suitable vector are well known in the art. Linking is generally accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide linkers are used in accordance with conventional practice. (See, Sambrook (1989) supra, and Bennett and Lasure, M
Where it is desired to obtain a fungal host cell having one or more inactivated genes known methods may be used (e.g. methods disclosed in U.S. Pat. No. 5,246,853, U.S. Pat. No. 5,475,101 and WO92/06209). Gene inactivation may be accomplished by complete or partial deletion, by insertional inactivation or by any other means which renders a gene nonfunctional for its intended purpose (such that the gene is prevented from expression of a functional protein). Any gene from a Trichoderma sp or other filamentous fungal host, such as an Aspergillus host, which has been cloned can be deleted, for example cbh1, cbh2, eg/1 and eg/2 genes. In some embodiments, gene deletion may be accomplished by inserting a form of the desired gene to be inactivated into a plasmid by methods known in the art. The deletion plasmid is then cut at an appropriate restriction enzyme site(s), internal to the desired gene coding region, and the gene coding sequence or part thereof is replaced with a selectable marker. Flanking DNA sequences from the locus of the gene to be deleted (preferably between about 0.5 to 2.0 kb) remain on either side of the marker gene. An appropriate deletion plasmid will generally have unique restriction enzyme sites present therein to enable the fragment containing the deleted gene, including the flanking DNA sequences and the selectable markers gene to be removed as a single linear piece.
Transformation, Expression and Culture of Host Cells:
Introduction of a DNA construct or vector into a host cell includes techniques such as transformation; electroporation; nuclear microinjection; transduction; transfection, (e.g., lipofection mediated and DEAE-Dextrin mediated transfection); incubation with calcium phosphate DNA precipitate; high velocity bombardment with DNA-coated microprojectiles; and protoplast fusion. General transformation techniques are known in the art (See, e.g., Ausubel et al., (1987), supra, chapter 9; and Sambrook (1989) supra, and Campbell et al., (1989) Curr. Genet. 16:53-56). The expression of heterologous protein in Trichoderma is described in U.S. Pat. No. 6,022,725; U.S. Pat. No. 6,268,328; Harkki et al. (1991); Enzyme Microb. Technol. 13:227-233; Harkki et al., (1989) Bio. Technol. 7:596-603; EP 244,234; EP 215,594; and Nevalainen et al., “The Molecular Biology of Trichoderma and its Application to the Expression of Both Homologous and Heterologous Genes”, in M
Preferably, genetically stable transformants are constructed with vector systems whereby the nucleic acid encoding an alpha amylase (e.g. an asAA having at least 90% sequence identity with SEQ ID NO: 3) is stably integrated into a host strain chromosome. Transformants may then purified by known techniques.
In one nonlimiting example, stable transformants including an amdS marker are distinguished from unstable transformants by their faster growth rate and the formation of circular colonies with a smooth, rather than ragged outline on solid culture medium containing acetamide. Additionally, in some cases a further test of stability may be conducted by growing the transformants on solid non-selective medium (i.e., medium that lacks acetamide), harvesting spores from this culture medium and determining the percentage of these spores which subsequently germinate and grow on selective medium containing acetamide. Alternatively, other methods known in the art may be used to select transformants.
In one embodiment, the preparation of Trichoderma sp. or Aspergillus sp. for transformation involves the preparation of protoplasts from fungal mycelia. (See, Campbell et al., (1989) Curr. Genet. 16:53-56). In some embodiments, the mycelia are obtained from germinated vegetative spores. The mycelia are treated with an enzyme that digests the cell wall resulting in protoplasts. The protoplasts are then protected by the presence of an osmotic stabilizer in the suspending medium. These stabilizers include sorbitol, mannitol, potassium chloride, magnesium sulfate and the like. Usually the concentration of these stabilizers varies between about 0.8 M and about 1.2 M. In some embodiments, it may be preferable to use sorbitol and in other embodiments it may be preferable to use magnesium sulfate (e.g., about a 1.2 M solution of sorbitol in the suspension medium or about a 0.8 M magnesium sulfate solution in the suspension medium).
Uptake of DNA into the host strain may be dependent upon the calcium ion concentration. Generally, between about 10 mM CaCl2 and 50 mM CaCl2 may be used in an uptake solution. Besides the need for the calcium ion in the uptake solution, other compounds generally included are a buffering system such as TE buffer (10 Mm Tris, pH 7.4; 1 mM EDTA) or 10 mM MOPS, pH 6.0 buffer (morpholinepropanesulfonic acid) and polyethylene glycol (PEG).
Usually a suspension containing the host cells or protoplasts, such as Trichoderma sp. or Aspergillus sp. protoplasts or cells, which have been subjected to a permeability treatment at a density of about 105 to about 107/mL, preferably about 2×106/mL, and also about 1× to 107 are used in transformations. In some embodiments, a volume of about 100 μL of these protoplasts or cells in an appropriate solution (e.g., 1.2 M sorbitol; 50 mM CaCl2) are mixed with the desired DNA. In some embodiments, a high concentration of PEG is added to the uptake solution. From 0.1 to 1 volume of 25% PEG 4000 can be added to the protoplast suspension. However, it is preferable to add about 0.25 volumes to the protoplast suspension. Additives such as dimethyl sulfoxide, heparin, spermidine, potassium chloride and the like may also be added to the uptake solution and aid in transformation. Similar procedures are available for other fungal host cells. (See, e.g., U.S. Pat. Nos. 6,022,725 and 6,268,328, both of which are incorporated by reference).
Generally, the mixture is then incubated at approximately 0° C. for a period of between 10 to 30 minutes. Additional PEG may be added to the mixture to further enhance the uptake of the desired gene or DNA sequence. In some embodiments, a 25% PEG 4000 is added in volumes of 5 to 15 times the volume of the transformation mixture; however, greater and lesser volumes may be suitable. The 25% PEG 4000 is preferably about 10 times the volume of the transformation mixture. After the PEG is added, the transformation mixture may be incubated either at room temperature or on ice before the addition of a sorbitol and CaCl2 solution. The protoplast suspension is then further added to molten aliquots of a growth medium. When the growth medium includes a growth selection (e.g., acetamide or an antibiotic) it permits the growth of transformants only.
Generally, cells are cultured in a standard medium containing physiological salts and nutrients (See, e.g., Pourquie, J. et al., B
Culture conditions are also standard, (e.g., cultures are incubated at approximately 28° C. in appropriate medium in shake cultures or fermenters until desired levels of asAA expression are achieved). Culture conditions for a given filamentous fungus are known in the art and may be found in the scientific literature and/or from the source of the fungi such as the American Type Culture Collection and Fungal Genetics Stock Center.
After fungal growth has been established, the cells are exposed to conditions effective to cause or permit the expression and secretion of an alpha amylase and also of an alpha amylase (e.g. asAA) and glucoamylase as defined herein. In cases where an asAA having GSH activity coding sequence is under the control of an inducible promoter, the inducing agent (e.g., a sugar, metal salt or antimicrobial), is added to the medium at a concentration effective to induce asAA expression.
Identification of Enzyme Activity:
In order to evaluate the expression of an alpha amylase (e.g. asAA having GSH activity) by a cell line that has been transformed with a heterologous polynucleotide encoding an alpha amylase encompassed by the invention, assays can be carried out at the protein level, the RNA level or by use of functional bioassays particular to alpha amylase activity and/or production. In general assays employed include, Northern blotting, dot blotting (DNA or RNA analysis), RT-PCR (reverse transcriptase polymerase chain reaction), or in situ hybridization, using an appropriately labeled probe (based on the nucleic acid coding sequence) and conventional Southern blotting and autoradiography.
In addition, the production and/or expression of an enzyme encompassed by the invention may be measured in a sample directly, for example, by assays directly measuring reducing sugars such as glucose in the culture media and by assays for measuring glucoamylase activity, expression and/or production. Substrates useful for assaying GSH activity include granular starch substrates. For example, glucose concentration may be determined by any convenient method such as by using glucose reagent kit No 15-UV (Sigma Chemical Co.) or an instrument such as Technicon Autoanalyzer. Also reference is made to glucose oxidase kits and glucose hexose kits commercially available from Instrumentation Lab. (Lexington, Mass.).
In addition, gene expression may be evaluated by immunological methods, such as immunohistochemical staining of cells, tissue sections or immunoassay of tissue culture medium, e.g., by Western blot or ELISA. Such immunoassays can be used to qualitatively and quantitatively evaluate expression of an asaA. The details of such methods are known to those of skill in the art and many reagents for practicing such methods are commercially available.
Alpha amylase activity may be, for example, measured by using the DNS method as described in Miller, G. L. (1959) Anal. Chem. 31:426-428. Glucoamylase activity may be assayed for example by the 3,5-dinitrosalicylic acid (DNS) method (See, Goto et al., (1994) Biosci. Biotechnol. Biochem. 58:49-54).
In some embodiments of the invention, the asAA (e.g. an alpha amylase having at least 80% sequence identity to SEQ Di NO: 3) produced by a Trichoderma or Aspergillus host will be greater than 1 gram protein per liter (g/L), greater than 2 g/L, greater than 5 g/L, greater than 10 g/L, greater than 20 g/L, greater than 25 g/L, greater than 30 g/L, greater than 50 g/L and also greater than 100 g/L of culture media.
In some embodiments, the amount of secreted glucoamylase will be at least 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80% and 95% of the total secreted protein from the host strain. In other embodiments, the amount of secreted glucoamylase will be greater than 50% of the total secreted protein. In some embodiments the amount of secreted glucoamylase will be less than 50% of the total secreted protein. In some embodiments, the amount of secreted glucoamylase will be greater than the amount of secreted asAA from an Aspergillus strain. In some embodiments the ratio of secreted glucoamylase to secreted asAA from the Aspergillus strain (GA/asAA) will be at least 1/1, at least 2/1, at least 4/1 at least 6/1 and at least 8/1. In some embodiments the ratio will be greater than 8/1.
In particular embodiments, the host is an overproducing glucoamylase host strain. In some embodiments, the overproducing host strain will be an Aspergillus sp. strain, such as an A. niger strain. In some embodiments, the Aspergillus overproducing glucoamylase strain is one that expresses a wild-type glucoamylase. One embodiment of an overproducing glucoamylase host strain is a recombinant Aspergillus niger strain comprising a polynucleotide encoding an endogenous glucoamylase and a polynucleotide encoding a heterologous alpha amylase having at least 90% sequence identity to SEQ ID NO: 3 or SEQ ID NO: 4. In some embodiments the produced glucoamylase is a full length A. niger glucoamylase and in other embodiments the glucoamylase is a truncated A. niger glucoamylase such as SEQ ID NO: 2 or SEQ ID NO: 13 of U.S. Pat. No. 6,352,851
Methods for Purifying Enzymes:
In general, an enzyme of according to the invention (such as an alpha amylase or glucoamylase) which is produced in cell culture is secreted into the medium and may be separated or purified, e.g., by removing unwanted components from the cell culture medium. In some cases, an enzyme may be produced in a cellular form necessitating recovery from a cell lysate. In such cases the enzyme is purified from the cells in which it was produced using techniques routinely employed by those of skill in the art. Examples include, but are not limited to, affinity chromatography (Tilbeurgh et al., (1984) FEBS Lett. 16:215); ion-exchange chromatographic methods (Goyal et al., (1991) Biores. Technol. 36:37; Fliess et al., (1983) Eur. J. App. Microbiol. Biotechnol. 17:314; Bhikhabhai et al., (1984) J. Appl. Biochem. 6:336; and Ellouz et al., (1987) Chromatography 396:307), including ion-exchange using materials with high resolution power (Medve et al., (1998) J. Chromatography A 808:153; hydrophobic interaction chromatography (Tomaz and Queiroz, (1999) J. Chromatography A 865:123; two-phase partitioning (Brumbauer, et al., (1999) Bioseparation 7:287); ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; and gel filtration using, e.g., Sephadex G-75.
Fermentations:
In some embodiments of the present invention, fungal cells expressing a heterologous alpha amylase are grown under batch or continuous fermentation conditions. A classical batch fermentation is a closed system, wherein the composition of the medium is set at the beginning of the fermentation and is not subject to artificial alterations during the fermentation. Thus, at the beginning of the fermentation the medium is inoculated with the desired organism(s). In this method, fermentation is permitted to occur without the addition of any components to the system. Typically, a batch fermentation qualifies as a “batch” with respect to the addition of the carbon source and attempts are often made at controlling factors such as pH and oxygen concentration. The metabolite and biomass compositions of the batch system change constantly up to the time the fermentation is stopped. Within batch cultures, cells progress through a static lag phase to a high growth log phase and finally to a stationary phase where growth rate is diminished or halted. If untreated, cells in the stationary phase eventually die. In general, cells in log phase are responsible for the bulk of production of end product.
A variation on the standard batch system is the “fed-batch fermentation” system, which also finds use with the present invention. In this variation of a typical batch system, the substrate is added in increments as the fermentation progresses. Fed-batch systems are useful when catabolite repression is apt to inhibit the metabolism of the cells and where it is desirable to have limited amounts of substrate in the medium. Measurement of the actual substrate concentration in fed-batch systems is difficult and is therefore estimated on the basis of the changes of measurable factors such as pH, dissolved oxygen and the partial pressure of waste gases such as CO2. Batch and fed-batch fermentations are common and well known in the art.
Continuous fermentation is an open system where a defined fermentation medium is added continuously to a bioreactor and an equal amount of conditioned medium is removed simultaneously for processing. Continuous fermentation generally maintains the cultures at a constant high density where cells are primarily in log phase growth.
Continuous fermentation allows for the modulation of one factor or any number of factors that affect cell growth and/or end product concentration. For example, in one embodiment, a limiting nutrient such as the carbon source or nitrogen source is maintained at a fixed rate an all other parameters are allowed to moderate. In other systems, a number of factors affecting growth can be altered continuously while the cell concentration, measured by media turbidity, is kept constant. Continuous systems strive to maintain steady state growth conditions. Thus, cell loss due to medium being drawn off must be balanced against the cell growth rate in the fermentation. Methods of modulating nutrients and growth factors for continuous fermentation processes as well as techniques for maximizing the rate of product formation are well known in the art of industrial microbiology.
Compositions:
A particularly useful enzyme composition according to the invention is a starch hydrolyzing enzyme composition (e.g. a granular starch hydrolyzing composition) which includes an alpha amylase having at least 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 3. In some embodiments, the alpha amylase (e.g. asAA) is obtained from the heterologous expression of asAA, such as the heterologous expression of an Aspergillus kawachi acid stable alpha amylase in a Trichoderma or Aspergillus host. In some embodiments the Aspergillus host is an overproducing glucoamylase host.
Another useful enzyme composition of the invention is a starch hydrolyzing enzyme composition (e.g. a granular starch hydrolyzing composition) which comprises a truncated alpha amylase (e.g. asAA) having at least 97%, 98% and 99% sequence identity to the sequence of SEQ ID NO: 9.
In further embodiments, an enzyme composition according to the invention will include a combination of alpha amylase enzymes which include a) intact asAA having GSH activity which includes a sequence having at least 85%, 90%, 95%, 96%, 97%, 98% and 99% identity to SEQ ID NO: 3 and b) a truncated alpha amylase. In some embodiments, the truncated alpha amylase will be a sequence having at least 96%, 97%, 98% and 99% sequence identity with the sequence of SEQ ID NO: 9.
In some embodiments, the amount of intact asAA having GSH activity compared to the total amount of asAA having GSH activity (intact plus truncated) in the enzyme composition will be at least about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, and 98%. In other embodiments, the ratio of intact asAA having GSH activity to truncated asAA having GSH activity in an enzyme composition according to the invention will be about 10% to 90%, 20% to 80%, 30% to 70%, 35% to 65%, 40% to 60%, 45% to 55%, 50% to 50%, 55% to 45%, 60% to 40%, 65% to 35%, 70% to 30%, 80% to 20% and 90% to 10% (intact to truncated). In some embodiments, the ratio of intact to truncated will be between about 40% to 60% and about 60% to 40%.
In some embodiments, the alpha amylase and optionally a glucoamylase produced by co-expression in the host will be available as a cell free filtrate (for example wherein the asAA is isolated from a culture medium), and in other embodiments, the alpha amylase is available in a culture medium containing the fungal host cells which express and secrete the alpha amylase (e.g., asAA having GSH activity). In a further aspect, the invention encompasses a fermentation or culture medium comprising an acid stable alpha amylase (asAA) having granular starch hydrolyzing activity produced from a culture of Trichoderma cells, said Trichoderma cells comprising a heterologous polynucleotide encoding the asAA which has at least 90% sequence identity with SEQ ID NO: 3.
In another embodiment, the invention encompasses a fermentation or culture medium comprising an acid stable alpha amylase (asAA) having granular starch hydrolyzing activity produced from a culture of Aspergillus cells, said Aspergillus cells comprising a heterologous polynucleotide encoding an asAA which has at least 90% sequence identity with SEQ ID NO: 3.
In another embodiment, the invention encompasses a fermentation or culture medium comprising an acid stable alpha amylase (asAA) and a glucoamylase wherein both the alpha amylase and glucoamylase are co-expressed from a culture of Aspergillus cells, said cells comprising a heterologous polynucleotide encoding an alpha amylase which has at least 90% sequence identity with SEQ ID NO: 3 and an endogenous polynucleotide coding for the glucoamylase.
In some embodiments, the alpha amylase and the glucoamylase in the culture medium are further recovered. The enzymes may be formulated for use in enzyme compositions for numerous applications. Some of these applications and compositions include but are not limited to for example starch hydrolyzing and saccharifying compositions, cleaning and detergent compositions (e.g., laundry detergents, dish washing detergents, and hard surface cleaning compositions), animal feed compositions, baking applications, such as bread and cake production, brewing applications, healthcare applications, textile applications, environmental waste conversion processes, biopulp processing, and biomass conversion applications.
In particular, the compositions encompassed by the invention are used in starch conversion, such as in the production of dextrose for fructose syrups, specialty sugars and also in alcohol and other end-product (e.g. organic acid, ascorbic acid) production.
As understood by those in the art, the quantity of alpha amylase (e.g., asAA having GSH activity) used in the compositions and methods of the present invention will depend on the enzymatic activity of the alpha amylase. In some embodiments, the range of an alpha amylase encompassed by the invention present in the enzyme compositions is from 0.001 to 80 SSU, 0.001 to 60 SSU, also 0.01 to 40 SSU; also 0.01 to 30 SSU; also 0.01 to 20 SSU; also 0.01 to 15 SSU; also 0.05 to 15 SSU and also 0.01 to 10 SSU per g ds.
Useful enzyme compositions according to the invention are enzyme compositions as described above which further comprise a secondary glucoamylase. A secondary glucoamylase is a glucoamylase obtained from a source that is different from the Aspergillus host, which comprises the heterologous polynucleotide encoding an alpha amylase encompassed by the invention (e.g. a polynucleotide encoding an alpha amylase having at least 90% sequence identity to SEQ ID NO: 3).
Glucoamylase (GA) (E.C. 3.2.1.3) enzymes, which may be useful in the compositions according to the invention may be wild type glucoamylases or genetically modified glucoamylases, which include variant and hybrid glucoamylases. In general, glucoamylases may be derived from bacteria, plants and fungal sources. Preferred glucoamylases useful in the compositions and methods of the invention are produced by several strains of filamentous fungi and yeast. In particular, glucoamylases secreted from strains of Aspergillus and Trichoderma are commercially important. Sources of these glucoamylases include: Aspergillus niger G1 and G2 glucoamylase and variants thereof (Boel et al., (1984) EMBO J. 3:1097-1102; WO 92/00381; WO 00/04136, WO 05/045018, see SEQ ID NO: 25 and U.S. Pat. No. 6,352,851); Aspergillus awamori glucoamylases (WO 84/02921 and WO 05/052148, see SEQ ID NO: 5); Aspergillus oryzae glucoamylases and variants thereof (Hata et al., (1991) Agric. Biol. Chem. 55:941-949) and Aspergillus shirousami (See, Chen et al., (1996) Prot. Eng. 9:499-505; Chen et al. (1995) Prot. Eng. 8:575-582; and Chen et al., (1994) Biochem J. 302:275-281). Glucoamylases are also obtained from strains of Talaromyces such as those derived from T. emersonii, T. leycettanus, T. duponti and T. thermophilus (WO 99/28488; U.S. Pat. No. RE: 32,153; and U.S. Pat. No. 4,587,215) and variants thereof; strains of Rhizopus, such as R. niveus and R. oryzae and variant thereof; strains of Mucor; strains of Trichoderma, such as T. reesei and T. viride; and strains of Humicola, such as H. grisea (See, Boel et al., (1984) EMBO J. 3:1097-1102; WO 92/00381; WO 00/04136; Chen et al., (1996) Prot. Eng. 9:499-505; Taylor et al., (1978) Carbohydrate Res. 61:301-308; U.S. Pat. No. 4,514,496; U.S. Pat. No. 4,092,434; WO 05/052148, see SEQ ID NO: 2 and 3, and Jensen et al., (1988) Can. J. Microbiol. 34:218-223). Other glucoamylases useful in the present invention include those obtained from Athelia rolfsii and variants thereof (U.S. Pat. No. 4,727,026; WO 04/111218 and SEQ ID NO: 26 of WO 05/045018).
Enzymes having glucoamylase activity used commercially are produced for example, from Aspergillus niger (trade name DISTILLASE, OPTIDEX L-400 and G ZYME G990 4X from Genencor International Inc.) or Rhizopus species (trade name CU.CONC from Shin Nihon Chemicals, Japan). Also the commercial digestive enzyme, trade name GLUCZYME from Amano Pharmaceuticals, Japan (Takahashi et al., (1985) J. Biochem. 98:663-671). Additional enzymes include three forms of glucoamylase (E.C.3.2.1.3) of a Rhizopus sp., namely “Gluc1” (MW 74,000), “Gluc2” (MW 58,600) and “Gluc3” (MW 61,400). Gluc1 finds particular use in the present invention.
Some GA enzymes are also granular starch hydrolyzing enzyme(s) (GSHE) (See e.g., Tosi et al., (1993) Can. J. Microbiol. 39:846-855). These GA-GSHEs not only have glucoamylase activity, but also are able to hydrolyze granular (raw) starch. GA-GSHEs have been recovered from fungal cells and particularly filamentous fungal cells such as Humicola sp., Aspergillus sp., Trichoderma sp. and Rhizopus sp. A Rhizopus oryzae GA-GSHE has been described in Ashikari et al., (1986) Agric. Biol. Chem. 50:957-964 and U.S. Pat. No. 4,863,864. Also reference is made to Rhizopus niveus. A Humicola grisea GA-GSHE is described by Allison et al., (1992) Curr. Genet. 21:225-229, Tosi et al., (1993) Can. J. Microbiol. 39: 846-852, Campos et al., (1995) App. And Environ. Microbiol. 61:2436-2438 and European Patent No., 171218. An Aspergillus awamori var. kawachi GA-GSHE is described by Hayashida et al., (1989) Agric. Biol. Chem. 53:923-929. An Aspergillus shirousami GA-GSHE is described by Shibuya et al., (1990) Agric. Biol. Chem. 54:1905-1914. One particular GA-GSHE preparation for use in the present invention includes enzyme preparations sold under the designation “M1” available from Biocon India, Ltd, India.
In one embodiment, a GA-GSHE enzyme may be derived from a strain of Humicola grisea, particularly a strain of H. grisea var. thermoidea (See, U.S. Pat. No. 4,618,579). In some preferred embodiments, the Humicola grisea GA-GSHE enzyme is recovered from fungi including ATCC 16453, NRRL (USDA Northern Regional Research Laboratory, Peoria, ILL) 15219, NRRL 15220, NRRL 15221, NRRL 15222, NRRL 15223, NRRL 15224 and NRRL 15225, as well as genetically altered strains thereof. These species produce enzymatic glucoamylase preparations that are immunologically the same (See, EP 0 171 218).
The amount of glucoamylase useful in an enzyme composition may be in the range of 0.001 to 30.0 GAU/g ds, also 0.001 to 25.0 GAU/g ds, also 0.01 to 25.0 GAU/g ds, also 0.1 to 25.0 GAU/g ds, also 0.01 to 20 GAU/g ds, also 0.01 to 15 GAU/g ds, also 0.01 to 10 GAU/g ds, also 0.1 to 10 GAU/g ds and also 0.05 to 5.0 GAU/g ds. The activity of a GA-GSHE preparation may be defined in terms of the glucoamylase activity.
Some useful enzymatic compositions include a mixture of an alpha amylase, such as asAA having at least 95% sequence identity to SEQ ID NO: 3 and a glucoamylase having 0.1 to 10 GAU/g ds. Another useful enzymatic composition includes a mixture of an asAA having at least 98% sequence identity to SEQ ID NO: 3 and a glucoamylase having 0.1 to 10 GAU/g ds. Yet another useful enzymatic composition includes a mixture of an alpha amylase having at least 98% sequence identity to SEQ ID NO: 9 and a glucoamylase having 0.1 to 10 GAU/g ds.
In some embodiments, the ratio of the activity of an alpha amylase encompassed by the invention (SSU) to GA activity (GAU) will be in the range of 40:1 to 1:40, also 30:1 to 1:30, also 20:1 to 1:20 and also 15:1 to 1:15. In further embodiments, the ratio (SSU to GAU) will be in the range of about 20:1 to 1:10; about 10:1 to 1:10; about 10:1 to 1:5; about 5:1 to 1:5, about 4:1 to 1:4; about 3:1 to 1:3; about 2:1 to 1:4 and also about 2:1 to 1:2. In some embodiments, the ratio of SSU to GAU will be between about 4:1 to 2:1.
In some embodiments, an alpha amylase, such as an asAA having GSH activity having at least 80% sequence with SEQ ID NO: 3 will be mixed with a slurry of a granular starch substrate in an amount of about 0.001 to 30 SSU per gram of dry solids or also in an amount of 0.01 to 15.0 SSU per gram of dry solids content of the slurry. In some embodiments, an asAA encompassed by the invention is added in an amount of about 0.01 to 10.0 SSU, about 0.01 to 5.0 SSU; about 0.05 to 10.0 SSU; about 0.05 to 5.0 SSU; about 0.1 to 10.0 SSU; about 0.1 to 5.0 SSU; about 0.1 to 2.0 SSU; about 0.25 to 2.5 SSU; about 0.5 to 5.0 SSU; about 0.5 to 2.5 SSU; and also about 0.5 to 1.5 SSU per gram of dry solids content of the slurry.
As understood by those in the art, the quantity of glucoamylase used in the method and compositions of the present invention depends on the enzymatic activity of the glucoamylase. In some embodiments, an amount of between 0.001 and 15.0 GAU of glucoamylase per gram (ds) slurry adjusted to 20-45% dry solids may be added. In some embodiments, the glucoamylase is added in an amount between 0.001 and 10 GAU; between 0.01 and 10.0 GAU; between 0.01 and 5.0 GAU; between 0.05 and 5.0 GAU: between 0.1 and 10.0 GAU; between 0.1 and 5.0 GAU; between 0.1 and 2.0 GAU; between 0.25 and 1.5 GAU of glucoamylase per gram (ds) slurry. In one embodiment, the dosage range for glucoamylase will be from 0.1 to 2.0 GAU/g (ds) slurry.
Additional enzymes may be included in the compositions and methods encompassed by the invention. These additional enzymes, which find use in the present invention include debranching enzymes such as pullulanases (E.C. 3.2.1.41) and isoamylases (E.C. 3.2.1.68). Such enzymes hydrolyze alpha-1,6-glucosidic bonds. Thus, during the hydrolysis of the starch, debranching enzymes remove successive glucose units from the non-reducing ends of the starch. Another enzyme that may be used in the compositions of the invention are beta-amylases (E.C. 3.2.1.2). These are exo-acting maltogenic amylases, which catalyze the hydrolysis of 1,4-alpha-glucosidic linkages in amylose, amylopectin and related glucose polymers. Some of these enzymes are characterized as having an optimum pH range from 4.5 to 7.0 and optimum temperature range from 40° C. to 65° C. Commercial beta-amylases are available for example SPEZYME BBA and OPTIMALT from Genencor International Inc.
Additional enzymes may include a second alpha amylase, one that is provided from a source other than the heterologous expression of an alpha amylase as encompassed by the invention (i.e an alpha amylase having at least 80% sequence identify with SEQ ID NO: 3). Examples of alpha amylases include both bacterial and fungal alpha amylases and variants thereof. Specific nonlimiting examples include alpha amylases from Bacillus amyloliquefaciens, Bacillus stearothermophilus, B. licheniformis and variants or hybrids thereof (U.S. Pat. No. 5,093,257; U.S. Pat. No. 6,093,562; U.S. Pat. No. 5,736,499; U.S. Pat. No. 5,958,739; U.S. Pat. No. 6,436,888; U.S. Pat. No. 6,867,031; WO 96/39528; WO 96/23874 and WO 05/001064). Commercially available alpha amylases are SPEZYME FRED and SPEZYME ETHYL (Genencor International Inc.). Cyclodextrin glucanotransferases (CGTases) (e.g. E.C. 2.4.1.19) and variants thereof may also find use in the invention (U.S. Pat. No. 5,278,059; U.S. Pat. No. 5,545,587 and WO 05/003337).
Further additional enzymes which may be used are proteases, such as fungal and bacterial proteases. Fungal proteases include for example, those obtained from Aspergillus, Trichoderma, Mucor and Rhizopus, such as A. niger, A. awamori, A. oryzae and M. miehei. Other enzymes include but are not limited to cellulases, such as endoglucanases; hemicellulases, such as mannases; lipases (e.g., E.C. 3.1.1.3), glucose oxidases, pectinases, xylanases, transglucosidases, alpha 1,6 glucosidases (e.g., E.C. 3.2.1.20) and cutinases (e.g. E.C. 3.1.1.74).
The effective amount of these enzymes to be included in the methods of the invention can be readily determined by one skilled in the art.
In some embodiments, an antimicrobial may be added to the compositions and fermentation medium of the invention. Antimicrobials are compounds that kill or inhibit the growth of microorganisms.
In one embodiment, an enzyme composition comprising an asaA as encompassed by the invention and in combination with a glucoamylase will be used for producing ethanol. In some embodiments, at least 8%, 10%, 12%, 14%, 16% and 18% ethanol will be produced using a composition of the invention. In some embodiments, the ethanol will be produced during a simultaneous saccharification and fermentation. In some embodiments, the enzyme composition comprising the alpha amylase and glucoamylase produced from the same Aspergillus strain will be contemporaneously combined with a slurry of a granular starch substrate and an ethanol producing microorganism and the mixture will be fermented in a single step. The slurry may have about 10-50% ds; about 10-45%; about 15-40%; about 20-40%; about 25-40%; or about 25-35% ds.
A granular starch substrate may be obtained from any plant part including stems, grains, roots and tubers. Particularly preferred plant sources include corn; wheat; rye; sorghum; rice; millet; barley; cassava; legumes, such as beans and peas; potatoes; sweet potatoes; bananas; sugarcane; and tapioca.
Specifically contemplated starch substrates are cornstarch and wheat starch. The starch from a grain may be ground or whole and includes corn solids, such as kernels, bran and/or cobs. In addition, the grain may be fractionated (e.g., endosperm, fiber or germ in corn or gluten, starch A or starch B in wheat). The starch may be highly refined raw starch or feedstock from starch refinery processes. Those of general skill in the art are well aware of available methods which may be used to prepare granular starch substrates for use in the methods encompassed by the invention. Some of these methods include dry milling of whole cereal grains using hammer mills and roller mills and wet milling.
Various starches are commercially available. For example, cornstarches are available from Cerestar, Sigma, and Katayama Chemical Industry Co. (Japan); wheat starches are available from Sigma; sweet potato starches are available from Wako Pure Chemical Industry Co. (Japan); and potato starch is available from Nakaari Chemical Pharmaceutical Co. (Japan).
Various references have reported on the amount of starch found in cereal grains and reference is made to The Alcohol Textbook, 3rd Ed. K. Jacques et al., Eds. 1999, Nottingham University Press. For example, corn contains about 60-68% starch; barley contains about 55-65% starch; millet contains about 75-80% starch; wheat contains about 60-65% starch; and polished rice contains 70-72% starch.
In some embodiments, a granular starch substrate is slurried (generally with water) and the slurry comprises i) about 10 to about 55% dry solids content (ds); ii) about 15 to about 50% dry solids content; iii) about 20 to about 45% dry solids content; iv) about 25 to about 45% dry solids content; v) about 30 to about 45% dry solids content; vi) about 30 to about 40% dry solids content; and also vii) about 30 to 35% dry solids content. In some embodiments, the granular starch slurry is contacted with an enzyme composition according to the invention at a temperature below the gelatinization temperature of the starch in the granular starch substrate to yield glucose.
The exact temperature used in accordance with the methods of the invention depends upon the specific starch substrate used. General starch gelatinization temperature ranges are disclosed in Swinkels pages 32-38 in S
In some embodiments, a method encompassed by the invention will be conducted at a pH range of between pH 3.0 to 7.0; between pH 3.0 to 6.0, between pH 3.0 to 5.0, between 3.5 to 6.0, between pH 3.5 to 5.0, and between 3.5 to 4.5.
In some embodiments, the residence time of the method is from about 2 to 300 hrs, but more typically from 2 to 120 hours. In some embodiments, the process is conducted from about 5 to 100 hours. In other embodiments, the process is conducted from about 5 to 80 hours. In still other embodiments, the process is conducted for at least 5 hours but less than 100 hours. In other embodiments, the process is conducted for at least about 10 hours but less than about 100 hours.
In some embodiments, at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 94%, 95%, 96%, 97%, 98% and 99% of the dry solids of the granular starch is hydrolyzed. In some embodiments, the granular starch substrate is completely hydrolyzed. In some embodiments, at least 90% of the granular starch is hydrolyzed in 100 hours. In certain embodiments, at least 90% of the granular starch substrate is hydrolyzed in a time period of 24 hours. In other embodiments, at least 95% of the granular starch substrate is hydrolyzed in a time period of 24 hours.
The yield of glucose (percent of the total solubilized dry solids) may be at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% and 98%. In some embodiments, the glucose may be used to produce high fructose syrups. In a preferred embodiment, the glucose is continually produced and substantially all of the glucose is used in the process to produce an end-product, such as ethanol and co-products such as DDGS. (Reference is made to M
The following examples are provided in order to demonstrate and further illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof. Indeed, it is contemplated that these teachings will find use in further optimizing the process systems described herein.
In the disclosure and experimental section which follows, the following abbreviations apply:
asAA having GSH activity (an acid-stable alpha amylase having granular starch hydrolyzing activity); AkAA (the acid stable alpha amylase having SEQ ID NO: 3 or SEQ ID NO: 4 and sometimes used interchangeably with asaA); GA (glucoamylase); wt % (weight percent); ° C. (degrees Centigrade); rpm (revolutions per minute); H2O (water); dH2O (deionized water); dlH2O (deionized water, Milli-Q filtration); aa (amino acid); bp (base pair); kb (kilobase pair); kD (kilodaltons); g or gm (grams); μg (micrograms); mg (milligrams); μL (microliters); ml and mL (milliliters); mm (millimeters); μm (micrometer); M (molar); mM (millimolar); μM (micromolar); U (units); V (volts); MW (molecular weight); sec (seconds); min(s) (minute/minutes); hr(s) (hour/hours); PAGE (polyacrylamide gel electrophoresis); DO (dissolved oxygen); phthalate buffer (sodium phthalate in water, 20 mM, pH 5.0); PBS (phosphate buffered saline [150 mM NaCl, 10 mM sodium phosphate buffer, pH 7.2]); SDS (sodium dodecyl sulfate); Tris (tris(hydroxymethyl)aminomethane); w/v (weight to volume); w/w (weight to weight); v/v (volume to volume); Genencor (Genencor International, Inc., Palo Alto, Calif.); DDGS (Distilleries Dry Grain plus Solids); MT (Metric ton); and EtOH (ethanol).
The following assays and methods are used in the examples provided below:
Glucoamylase Assay:
Glucoamylase activity was measured using a well-known assay which is based on the ability of glucoamylase to catalyze the hydrolysis of p-nitrophenyl-alpha-D-glucopyranoside (PNPG) to glucose and p-nitrophenol. At an alkaline pH, the nitrophenol; forms a yellow color that is proportional to glucoamylase activity and is monitored at 400 nm and compared against an enzyme standard measured as a GAU.
The measurement of acid-stable alpha amylase activity is based on the degree of hydrolysis of soluble potato starch substrate (4% ds) by an aliquot of the enzyme sample at pH 4.5, 50° C. The reducing sugar content is measured using the DNS method as described in Miller, G. L. (1959) Anal. Chem. 31:426-428. One unit of the enzyme activity (SSU, soluble starch unit) is equivalent to the reducing power of 1 mg of glucose released per minute at the specific incubation conditions.
Determination of Total Starch Content:
The enzyme-enzyme starch liquefaction and saccharification process (dual enzyme method) was used to determine the total starch content. In a typical analysis, 2 g of the dry sample was taken in a 100 ml Kohlraucsh flask and 45 ml of MOPS buffer, pH 7.0 was added. The slurry was well stirred for 30 min. SPEZYME FRED (1:50 diluted in water), 1.0 ml was added and heated to boiling for 3-5 min. The flask was placed in an autoclave maintained at 121° C. for 15 min. After autoclaving the flask was placed in a water bath at 95° C. and 1 ml of 1:50 dilutes SPEZYME FRED was added and incubated for 45 min. The pH was adjusted to pH 4.2 and the temperature was reduced to 60° C. This was followed by addition of 20 ml acetate buffer, pH 4.2. Saccharification was carried out by adding 1.0 ml of 1:100 diluted OPTIDEX L-400 (Glucoamylase from Genencor International Inc.) and the incubation was continued for 18 hr at 60° C. The enzyme reaction was terminated by heating at 95° C. for 10 min. The total sugar composition was determined by HPLC analysis using glucose as a standard. The soluble starch hydrolysate from water extraction of a sample at room temperature without enzymatic treatment was subtracted from the total sugar.
Residual Starch Iodine Test:
A sample of the beer (fermentation broth) was centrifuged in 2 ml plastic centrifuge tubes. The supernatant was decanted and the tube containing the pellet was placed in an ice bath. Several drops of 0.025N iodine solution (0.1N iodine from VWR Cat. No. VW3207-1 diluted 4×) was added to the pellet and mixed. A positive (+) starch shows a range of color from blue to purple and the intensity of color is directly proportional to the concentration of starch. A negative result (−) remains yellowish.
Total Protein Analysis:
The total nitrogen (N) in the sample preparations was determined using the Kjeldhal method (American Assoc. Cereal Chemists (AACC), (1983), Methods 22B60 8th Ed. St Paul, Minn.). Protein content was calculated by 6.25× total N.
Ethanol and Carbohydrate Determinations:
Ethanol and carbohydrate composition of the samples were determined using the HPLC method as described herein: a) 1.5 mL Eppendorf centrifuge tube was filled with fermenter beer and cooled on ice for 10 min; b) the sample tube was centrifuged for 1 min in Eppendorf table top centrifuge; c) a 0.5 mL sample of the supernatant was transferred to a test tube containing 0.05 mL of Kill solution (1.1N H2SO4) and allowed to stand for 5 min; d) 5.0 mL of water was added to the test tube sample and then filtered into a HPLC vial through 0.45 μm Nylon Syringe Filter; and then run on HPLC.
HPLC conditions:
a) Ethanol System: Column: Phenomenex Rezex Organic Acid Column (RHM-Monosaccharide) #00H-0132-KO (Equivalent to Bio-Rad 87H); Column Temperature: 60° C.; Mobile Phase: 0.01 N H2SO4; Flow Rate: 0.6 mL/min; Detector: RI; and Injection Volume: 20 μL
b) Carbohydrate System: Column: Phenomenex Rezex Carbohydrate (RCM-Monosaccharide) #00H-0130-KO (Equivalent to Bio-Rad 87H); Column Temperature: 70° C.; Mobile Phase: Nanopure DI H2O; Flow Rate: 0.8 mL/min; Detector: RI; and Injection Volume: 10 μL (3% DS material).
The column separates based on the molecular weight of the saccharides, which are designated as DP1 (monosaccharides); DP2 (disaccharides); DP3 (trisaccharides) and DP+4 (oligosaccharide sugars having a degree of polymerization greater than 3).
Preparation of asaA from the Heterologous Expression in Trichoderma reesei Used in the Examples:
At the end of the fermentation of the T. reesei, which expresses asaA (prepared according to examples 2 and 3), the biomass was separated by centrifugation and the clear culture filtrate was concentrated using a 10,000 molecular weight cut-off ultrafiltration membrane. This ultra filtrated concentrate having (90 SSU/g) was used.
Preparation of Aspergillus niger Glucoamylase Used in the Examples was as Follows:
A selected Aspergillus niger strain as described in U.S. Pat. No. 3,249,514 was used. After fermentation, fungal mycelia were separated using conventional separation methods including filtration and centrifugation. The clear filtrate was concentrated by ultrafiltration at 5° C. to a specified activity.
Cloning the Aspergillus kawachi acid-stable alpha-amylase gene
Genomic DNA was extracted from an overnight culture of A. kawachi mycelia. The FastDNA Kit (QbioGene, Carlsbad, Calif.) SPIN™ protocol was used according to the manufacturer's instructions for fungi. For homogenization, the sample was processed for 30 sec at speed 4.0 on a FastPrep Instrument. PCR primers were designed, based on the asaA sequence of A. Kaneko, et al. (Kaneko et al., (1996), J. Ferm Bioeng 81:292-298).
(A). For construction of the T. reesei expression vector, the sequence of the forward cloning primer, alph6, was CACCATGAGAGTGTCGACTTCAAG (SEQ ID NO. 6) and the sequence of the reverse cloning primer, Akaa3 was CTACCTCCACGTATCAACCAC (SEQ ID NO. 7). The forward primer contained a motif for directional cloning into the pENTR/D vector (Invitrogen). The gene was amplified from the genomic DNA with Pfu Turbo DNA polymerase (Stratagene, La Jolla, Calif.).
The 2.36 kb PCR product was purified by gel extraction (Gel Purification kit, Qiagen) and cloned into pENTR/D, according to the Invitrogen Gateway system protocol. The vector was then transformed into chemically competent Top10 E. coli (Invitrogen) with kanamycin selection. Plasmid DNA from several clones was digested with restriction enzymes to confirm the correct size insert. The alpha-amylase gene insert was sequenced (Sequetech, Mountain View, Calif.) from several clones (SEQ ID NO:1). Plasmid DNA from one clone, pENTR/D_Akaa#11, was added to the LR clonase reaction (Invitrogen Gateway system) with pTrex3g/amdS destination vector DNA. Recombination, in the LR clonase reaction, replaced the CmR and ccdB genes of the destination vector with the A. kawachi asaA from the pENTR/D vector. This recombination directionally inserted asaA between the cbhI promoter and terminator of the destination vector. Recombination site sequences of 48 and 50 bp remained upstream and downstream, respectively, of the alpha amylase. An aliquot of the LR clonase reaction was transformed into chemically competent Top10 E. coli and grown overnight with carbenicillin selection. Plasmid DNA from several clones was restriction digested to confirm the correct insert size. For removal of the fungal cassette from the bacterial plasmid, the Stratagene QuickChange protocol was followed to add an EcoRI site 3′ to the amdS gene. The sequence of the entire fungal cassette was confirmed. Plasmid DNA from clone, pTrex3g_Akalpha#1 (
(B). For construction of the Aspergillus niger expression vector, the sequence of the forward cloning primer, alpha 7, was 5′-GCGCGCTACGTAATGAGAGTGTCGACTTC (SEQ ID NO: 11) and the sequence of the reverse cloning primer, rsh46r, was 5′ GCGCGCTACGTACTACCTCCACGTATC (SEQ ID NO: 12). The gene was amplified from the genomic DNA with pfu Turbo DNA polymerase (Stratagene, La Jolla, Calif.).
The 2.36 kb PCR product was purified by gel extraction (Gel Purification kit, Qiagen) and cloned into pCR-BluntII-TOPO (Zero Blunt TOPO PCR cloning kit, Invitrogen) according to the manufacturer's protocol. The vector was transformed into One Shot® Top10 E. coli (Invitrogen) with kanamycin selection. Plasmid DNA from several clones was digested with restriction enzyme to confirm the correct size insert. The alpha amylase insert was sequenced (Sequetech, Mountain View, Calif.) from several clones (SEQ ID NO: 1). The sequenced 2.36 kb asaA gene was excised from the vector (clone TOPO-SnaBaa23) with restriction enzyme SnaBI and purified by gel extraction. Vector pSL898-MunI (
E. coli Clone #31, pSL902_AkAA (
A Trichoderma reesei spore suspension was spread onto the center ˜6 cm diameter of an MABA transformation plate (150 μl of a 5×107−5×108 spore/ml suspension). The plate was then air dried in a biological hood. The stopping screens (BioRad 165-2336) and macrocarrier holders (BioRad 1652322) were soaked in 70% ethanol and air dried. DriRite desiccant was placed in small Petri dishes (6 cm Pyrex) and overlaid with Whatman filter paper. The macrocarrier holder containing the macrocarrier (BioRad 165-2335) was placed flatly on top of filter paper and the Petri dish lid replaced.
A tungsten particle suspension was prepared by adding 60 mg tungsten M-10 particles (microcarrier, 0.7 micron, BioRad #1652266) to an Eppendorf tube. 1 ml ethanol (100%) was added. The tungsten was votexed in the ethanol solution and allowed to soak for 15 minutes. The Eppendorf tube was microfuged briefly at maximum speed to pellet the tungsten. The ethanol was decanted and washed three times with sterile distilled water. After the water wash was decanted the third time, the tungsten was resuspended in 1 ml of sterile 50% glycerol. The tungsten was prepared fresh at least every two weeks.
The transformation reaction was prepared by adding 25 μl of suspended tungsten to a 1.5 ml Eppendorf tube for each transformation. Subsequent additions were made in order, 0.5-5 μl DNA (XbaI-digested expression cassette), 25 μl 2.5 M CaCl2, 10 μl 0.1 M spermidine. The reaction was vortexed continuously for 5-10 minutes, keeping the tungsten suspended. The Eppendorf tube was then microfuged briefly and decanted. The tungsten pellet was washed with 200 μl of 70% ethanol, microfuged briefly to pellet and decanted. The pellet was washed with 200 μl of 100% ethanol, microfuged briefly to pellet, and decanted. The tungsten pellet was resuspended in 24 μl 100% ethanol. The Eppendorf tube was placed in an ultrasonic water bath for 15 seconds and 8 μl aliquots were transferred onto the center of the desiccated macrocarriers. The macrocarriers were left to dry in the desiccated Petri dishes.
A He tank was turned on to 1500 psi. 1100 psi rupture discs (BioRad 165-2329) were used in the Model PDS-1000/He Biolistic Particle Delivery System (BioRad). When the tungsten solution was dry, a stopping screen and the macrocarrier holder were inserted into the PDS-1000. An MABA plate, containing the target T. reesei spores, was placed 6 cm below the stopping screen. A vacuum of 29 inches Hg was pulled on the chamber and held. The He Biolistic Particle Delivery System was fired. The chamber was vented and the MABA plate removed for incubation at 28° C. until colonies appeared (5 days).
With reference to this Example 2 the following solutions were prepared,
Modified amdS Biolistic agar (MABA) per liter included: Part I, 1000× salts, 1.0 ml; Noble agar, 20 g made in 500 ml in dH2O. Adjusted to pH to 6.0 and autoclaved. Part II, Acetamide, 0.6 g; CsCl, 1.68 g; Glucose, 20 g; KH2PO4, 15 g; MgSO4.7H2O, 0.6 g; and CaCl2.2H2O, 0.6 g made in 500 ml dH2O. Adjusted to pH to 4.5 and 0.2 micron filter sterilized; left in 50° C. oven to warm, agar was added, mixed and poured into plates and stored at room temperature.
1000× Salts per liter=FeSO4.7H2O, 5 g; MnSO4.H2O, 1.6 g; ZnSO4.7H2, 1.4 g; COCl2.6H2O, 1 g brought up to 1 L with dH2O, and 0.2 micron filter sterilized.
A 1-2 cm2 agar plug of a sporulated mycelia (grown on potato dextrose agar (PDA), Difco for 5 days at 30° C.) was inoculated into 50 ml of YEG (5 g/L yeast extract plus 20 g/L glucose) broth in a 250 ml, 4-baffle shake flask and incubated at 30-37° C. for 16-20 hours at 200 rpm. The mycelia were recovered by transferring the shake flask contents into 50 ml conical tubes and spinning at 2500 rpm for 10 minutes. The supernatant was discarded and the mycelial pellet was transferred into a 250 ml, 0.22 m CA or PES Corning filter bottle containing 40 ml of filtered β-D-glucanase solution. The solution was incubated at 30° C., 200 rpm, for 2 hours to generate protoplasts. Protoplasts were harvested by filtration, through sterile Miracloth (CalBiochem, La Jolla, Calif.), into a 50 ml conical tube. The protoplasts were pelleted by centrifugation at 2000 rpm for 5 minutes and the supernatant discarded. Protoplast pellets were washed once with 50 ml of 1.2 M sorbitol; centrifuged (2000 rpm, 5 min.) and supernatant was discarded. The pellet was washed with 25 ml of sorbitol/CaCl2. A haemocytometer was used to count the protoplasts and then pelleted by centrifugation at 2000 rpm for 5 min. The supernatant was discarded and protoplast pellets resuspended in a volume of sorbitol/CaCl2 sufficient to generate a protoplast solution with a protoplast concentration of 1.25×108/ml.
For each transformation, an aliquot of 20 μg of expression vector DNA (in a volume no greater than 20 μl) was transferred into 15 ml conical tubes, on ice. Protoplast suspension (200 μl) and 50 μl PEG solution was added to each tube. This was mixed gently and incubated on ice for 20 min. PEG (2 ml) solution was added to each transformation tube and incubated at room temperature for 5 minutes. 4 ml sorbitol/CaCl2 solution was added to each tube (total volume 6.2 ml) and mixed gently. Then 2 ml of the transformation mixture was added to each of 3 molten (50° C.) top agar tubes. Each top agar mixture was poured onto a separate transformation plate and incubated at 30° C. for four to seven days.
For transformation with amdS selection, acetamide/sorbitol plates and top agar were used. Selection plates were the same as transformation plates, but without sorbitol. Putative transformants were purified by transferring isolated colonies to fresh selective media containing acetamide.
Media and solutions were prepared as follows. 40 ml β-D-glucanase solution—600 mg β-D-glucanase (InterSpex Products Inc., San Mateo, Calif.) and 400 mg MgSO4.7H2O was dissolved in 40 ml 1.2M sorbitol. 200 ml PEG mix—50 g PEG 4000 (BDH Laboratory Supplies Poole, England) and 1.47 g CaCl2.2H2O was dissolved in 200 ml dlH2O. The PEG mix is made fresh at least every month. Sorbitol/CaCl2 solution—50 mM CaCl2 is dissolved in 1.2M sorbitol. Acetamide/sorbitol agar—Part 1: Dissolved 0.6 g acetamide (Aldrich, 99% sublime.), 1.68 g CsCl, 20 g glucose, 20 g KH2PO4, 0.6 g MgSO4.7H2O, 0.6 g CaCl2.2H2O, 1 ml 1000× salts (see below) in 200 ml dlH2O, adjusted to pH 5.5, brought volume up to 300 mls with dH2O, and this is filter sterilized. Part II: 20 g Noble agar and 218 g sorbitol were added to a 1 L cylinder, brought to volume (700 mls) with dlH2O, and autoclaved. Part II was added to Part I for a final volume of 1 L. (1000× Salts—5 g FeSO4.7H2O, 1.6 g MnSO4.H2O, 1.4 g ZnSO4.7H2O, and 1 g CoCl2.6H2O are combined and brought up to 1 L volume with dlH2O. This is then filtered sterilized.
A 250 ml, 4-baffle shake flask containing 100 ml of WCWM or WCWM+CD broth was inoculated with an −80° C. stock of a strain of Aspergillus niger mycelia which overexpress wild-type endogenous glucoamylase and which is derived from ATCC 14916. The culture was grown at 30° C. for 48-72 hours, 300 rpm. A 10% transfer was made into fresh WCWM or WCWM+CD shake flask. The second stage cultures were grown for 24 to 72 hours, 30° C., 300 rpm. Mycelia was harvested through a sterile Miracloth filter and washed with Solution A, or mycelia were spun down in an IEC swinging bucket centrifuge (2000 rpm). Washed mycelia was aseptically transferred into 40 ml of protoplasting solution and incubated at 30° C., 200 rpm, for 1-2 hours, protoplasting progress was monitored microscopically. The protoplasting reaction was filtered through sterile Miracloth, into two 50 ml sterile disposable centrifuge tubes and the volume brought up to 45 mls each with Solution B. The protoplasts were centrifuged at 2500 rpm for 5 minutes to obtain pellets and the supernatant was discarded. The pellet was washed twice more with 20 ml volumes of Solution B. The pellet was resuspended in 10 ml Solution B and protoplasts counted using a haemocytometer. Protoplasts were again centrifuged and the supernatant discarded. Protoplasts were resuspended, in Solution B to yield ˜1×107/100 μl. On ice, 100 μl protoplast solution was added to pre-chilled 15 ml tubes, one tube per transformation. 10 μg DNA was added in a volume not exceeding 10 μl. Solution C (12.5 μl) was added, mixed gently, and incubated on ice for 20 minutes.
MMSA top agar (3 tubes of 10 ml each, per transformation) was melted and maintained at 55° C. Protoplasts were removed from the ice and Solution C (1 ml) and Solution B (2 ml) were added to each tube and the tubes were mixed gently. 1 ml of the protoplast mixture was added to each of the 3 top agar tubes and the top agar was poured onto MMSA plates. This was repeated for each transformation and plates were incubated for 4-7 days at 30° C.
Solution A (per 500 ml)—0.44 g K2HPO4; 0.34 g KH2PO4; 48.156 g anhydrous MgSO4 (FW 120.37); and dlH2O were added for a final volume of 500 ml, pH 5.5. The solution was filter sterilized and stored at room temperature.
Protoplasting solution—180 units beta-D-glucanase (InterSpex Products, Inc., CA) or 450 mg beta-D-glucanase and 150 mg Driselase (InterSpex Products, Inc.) were dissolved in 40 ml Solution A and the solution was filter sterilized, 0.2 micron.
Solution B (per 500 ml)—5 ml 1M Tris, pH 7.5; 2.77 g CaCl2 (FW 110.99); 109.32 g Sorbitol (FW 182.2; 1.2M); and dlH2O were added for a final volume of 500 ml. This solution was filter sterilized and stored at room temperature.
Solution C (per 500 ml)—250 g PEG 4000; 2.77 g CaCl2; 5 ml 1M Tris, pH 7.5; and dlH2O were added for a final volume of 500 ml. The solution was filter sterilized.
MMS Agar—Dissolved in 1 L dlH2O, 6 g/L NaNO3; 0.52 g/L KCl; 1.52 g/L KH2PO4; 218.5 g/L D-Sorbitol; 1 ml/L Trace elements (see below); 10 g/L agar (low melt agarose in the top agar). Autoclaved. Post-sterilization, aseptically added 10 ml 50% glucose and 1.25 ml 20% MgSO4.7H2O.
MMSA agar, the nitrate in the MMS was replaced with 0.59 g/L acetamide and 3.4 g/L CsCl.
Trace Elements Solution—Dissolved in 250 ml dlH2O, 1 g/L FeSO4.7H2O; 8.8 g/L ZnSO4.7H2O; 0.4 g/L CuSO4.5H2O; 0.15 g/L MnSO4.4H2O; g/L Na2B4O7.10H2O; 50 mg/L (NH4)6Mo7O24.4H2O. Mixed and added 0.2 ml concentrated HCl to dissolve and brought up to 1 L with dlH2O and filter sterilized.
WCWM broth (1 liter)=(NH4)2SO4, 3.5 g; DIFCO Yeast Extract, 4 g; Potato Dextrose Starch, 6 g; Mazu, 1 ml and Cerelose, 2.2 g.
WCWM+CD (1 liter)=(NH4)2SO4, 3.5 g; Tastone 210 Yeast Extract, 4 g; Potato Dextrose Broth, 20 g; and DIFCO Czapek Dox, 20 g.
(A). Trichoderma Clones—
In general, the fermentation protocol as described in Foreman et al. (Foreman et al. (2003) J. Biol. Chem. 278:31988-31997) was followed. More specifically, duplicate fermentations were run for each of the strains displayed in
Samples were obtained at regular intervals to monitor the progress of the fermentation. Collected samples were spun in a 50 ml centrifuge tube at ¾ speed in an International Equipment Company (Needham Heights, Mass.) clinical centrifuge. Sample supernatants were run of 4-12% BIS-TRIS SDS-PAGE gels, under reducing conditions with MOPS (morpholinepropanesulfonic acid) SDS running buffer and LDS sample buffer (
In additional fermentations, sample supernatants were run as basically described above. However, different proportions of intact and truncated forms of Tr-asaA were obtained.
(B). Aspergillus Clones—
Expression of both glucoamylase and A. kawachi alpha amylase was analyzed in Aspergillus niger transformants (obtained as described above). Glucoamylase activity and alpha amylase activity were measured by HPLC from sample supernatants from transformants. Of 27 transformants analyzed, at least 22 transformants produced over 0.5 mg/ml of AkAA. In addition at least 22 transformants produced at least 25% of the glucoamylase of the parental control (on an activity basis). At least 6 of these transformants produced over 1.5 mg/ml AkAA. Some of these results are illustrated below in Table 1.
Samples of AkAA recombinantly produced in a Trichoderma reesei (Tr-asaA) as described above and samples of native asaA were diluted to equal protein concentrations with 20 mM acetate buffer at pH 4.5. Reactions were run in 100 mM citrate/NaOH buffers at 50° C. for 30 minutes at pH levels 3 to 7. 1.0 mL of the reaction was added to 5 mL of 10% corn starch (Cargill Foods, MN) in 100 mM acetate, pH 4.5 in sample tubes. The tubes were shaken at 50° C. for 20 minutes. Then 0.5 mL 2.0% NaOH was added. Tubes were spun and 0.5 mL of the supernatant were assayed for reducing sugars using the Dinito Salicylic Acid (DNS) Assay (Goto et al., (1994) supra). The results are depicted in
AkAA produced in Trichoderma reesei was evaluated at two levels of glucoamylase (GA) from a cell free culture filtrate (0.5 and 1.0 GAU/g). The glucoamylase was obtained from an Aspergillus niger composition. Thirty six percent corn flour slurry was prepared containing dry corn steep (2.5% of corn flour). The pH of the slurry was adjusted to 4.8 with dilute sulfuric acid. The total dry solids of the slurry were 33.85%. Fermentations were carried out in 125 ml flasks containing 100 gm of mash (slurry). The desired levels of enzymes were added then 3 ml of propagated yeast slurry was added to start the fermentation. The yeast inoculum was prepared by adding 0.26 gm of dry Fali yeast to 100 gm of mash containing GA activity at 0.9 GAU/g of raw material solids. This slurry was placed in a 32° C. water bath and gently mixed for about 17 hours. At various time intervals samples of the fermentation (beer) were taken for HPLC analysis. After 72 hours, the fermentations were terminated and the beer was dried at 60° C. to obtain the distillers dry grains plus solubles (DDGS).
The starch content of the DDGS was determined and the insoluble solids of the beer after terminating the fermentation were spot checked for starch by the addition of Iodine. Table 2 summarizes ethanol levels, iodine stain of the mash solids and % starch of the DDGS.
Commercial alpha amylases from different sources were compared with Tr-asaA under the simultaneous saccharification and fermentation conditions in the presence of glucoamylase from a commercial source of GA at 0.5 GAU/g of ds. The activity of the commercial alpha amylases was determined using the soluble starch substrate (SSU) method assay as described earlier.
Ethanol fermentation was carried out using whole ground corn as described in Example 7. Alpha amylases from various sources were added at 1.0 SSU/g of ground corn and glucoamylase was added at 0.5 GAU/g.
Alpha amylases included AkAA expressed and produced from T. reesei having SSU/ml, 90; SPEZYME LT AA (Bacillus amyloliquefaciens) having SSU/ml, 2,759); SPEZYME FRED (Bacillus licheniformis) having SSU/ml, 4,842; SPEZYME Ethyl (Bacillus stearothermophilus) having SSU/ml, 22,082; and CLARASE L (Aspergillus oryzae) having SSU/ml, 23,087.
The samples were taken during the course of the fermentation and analyzed for ethanol content. After the fermentation, the insoluble solids (DDGS) were separated and the residual starch content of the corn mash at pH 5.0 was determined. The results are summarized in Table 3.
Whole ground corn substrate was subjected to a conventional dry milling process for fuel alcohol fermentation using a hammer mill to reduce particle size. Three different mashes were prepared.
Treatment 1 (Trt 1) is a high temperature treatment, which involved a batch liquefaction of a 36% ds corn flour slurry containing 0.9% dry corn steep (DCS) with 3.5 U/g SPEZYME ETHYL at pH 5.6 by jet cooking according to the prior art procedures. The slurry was place in a 90° C. bath for 1.5 hours, mixed and then cooled to 30° C. with a pH adjustment to 5.0 with dilute sulfuric acid. The slurry was further diluted with water to 32.71% ds.
Treatment 2 (Trt 2) is a low temperature treatment. The mash was prepared by incubating a 36% corn flour slurry containing 0.9% DCS with the pH adjusted to 5.0 with dilute sulfuric acid at 60° C. for three hours. Prior to incubation 0.05 GAU/g of glucoamylase was added.
Treatment 3 (Trt 3) is a room temperature treatment (no heat treatment)—a corn slurry was obtained at room temperature prior to use in the fermentation with 0.5 GAU glucoamylase/g of corn and 1.0 SSU/g corn of AkAA produced in Trichoderma reesei.
Yeast fermentation was then carried out on each treatment as described in example 7.
After the fermentation, ethanol yield was determined and the insoluble solids from each treatment were separated by centrifugation, dried at 60° C. and the total carbohydrate content and nitrogen content were determined. The results are illustrated in Table 4.
Ethanol production (% v/v) was evaluated at a glucoamylase dosing level of 0.75 GAU/g ds and at an alpha-amylase dosing level of 9.90 SSU/g ds for transformant #10 and 4.29 SSU/g ds for transformant #26 (see Example 5B, transformant #10 and transformant #26). A 100 g corn slurry having 33% DS was prepared from Azure corn flour (8.95% moisture). The pH of the slurry was adjusted to pH 4.5 and fermentations were carried out with the addition of 1 mL of 20% Fali yeast (400 ppm) at 32° C. in 125 ml flasks. Ethanol (% v/v) in the supernatant was measured at 24, 48 and 70 hours.
The present application is a continuation of U.S. patent application Ser. No. 11/270,864, filed Nov. 8, 2005, now U.S. Pat. No. 7,332,319 which is a continuation-in-part application of U.S. patent application Ser. No. 11/136,244 filed May 24, 2005, now U.S. Pat. No. 7,354,752 which claims priority to U.S. Provisional Patent Application Ser. No. 60/575,175, filed May 27, 2004, expired; U.S. Provisional Patent Application Ser. No. 60/605,437, filed Aug. 30, 2004, expired; International Application No. PCT/US04/040040, filed Nov. 30, 2004; International Application No. PCT/US04/041276, filed Dec. 9, 2004; and U.S. Provisional Patent Application Ser. No. 60/647,925 filed Jan. 28, 2005, and is a continuation-in-part application of U.S. patent application Ser. No. 10/999,886, filed Nov. 30, 2004, now U.S. Pat. No. 7,037,704 which claims priority to U.S. Provisional Application Ser. No. 60/605,437, filed Aug. 30, 2004, expired and U.S. Provisional Application Ser. No. 60/575,175, filed May 27, 2004, expired; the contents of all of the above are fully incorporated by reference herein.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3249514 | Bode | May 1966 | A |
| 4092434 | Yoshizumi et al. | May 1978 | A |
| 4514496 | Yoshizumi et al. | Apr 1985 | A |
| RE32153 | Tamura et al. | May 1986 | E |
| 4587215 | Hirsh | May 1986 | A |
| 4618579 | Dwiggins et al. | Oct 1986 | A |
| 4863864 | Ashikari et al. | Sep 1989 | A |
| 5093257 | Gray | Mar 1992 | A |
| 5246853 | Clarkson et al. | Sep 1993 | A |
| 5278059 | Sugimoto et al. | Jan 1994 | A |
| 5364770 | Berka et al. | Nov 1994 | A |
| 5472864 | Bower | Dec 1995 | A |
| 5475101 | Ward et al. | Dec 1995 | A |
| 5545587 | Sugimoto et al. | Aug 1996 | A |
| 5736499 | Mitchinson et al. | Apr 1998 | A |
| 5874276 | Fowler et al. | Feb 1999 | A |
| 5958739 | Mitchinson et al. | Sep 1999 | A |
| 6022725 | Fowler et al. | Feb 2000 | A |
| 6093562 | Bisgard-Frantzen et al. | Jul 2000 | A |
| 6268328 | Mitchinson et al. | Jul 2001 | B1 |
| 6352851 | Nielsen et al. | Mar 2002 | B1 |
| 6436888 | Svendsen et al. | Aug 2002 | B1 |
| 6590078 | Ward et al. | Jul 2003 | B2 |
| 6867031 | Bisgard-Frantzen et al. | Mar 2005 | B2 |
| Number | Date | Country |
|---|---|---|
| 0 171 218 | Oct 1993 | EP |
| 0 244 234 | Nov 2001 | EP |
| 0 215 594 | Oct 2003 | EP |
| 1995099979 | Apr 1995 | JP |
| WO 8402921 | Aug 1984 | WO |
| WO 9200381 | Jan 1992 | WO |
| WO 9206209 | Apr 1992 | WO |
| WO 9623874 | Aug 1996 | WO |
| WO 9639528 | Dec 1996 | WO |
| WO 9928488 | Jul 1999 | WO |
| WO 0004136 | Jan 2000 | WO |
| WO 2004080923 | Sep 2004 | WO |
| WO 2004111218 | Dec 2004 | WO |
| WO 2005001036 | Jan 2005 | WO |
| WO 2005001064 | Jan 2005 | WO |
| WO 2005003311 | Jan 2005 | WO |
| WO 2005003337 | Jan 2005 | WO |
| WO 2005045018 | Jan 2005 | WO |
| WO 2005052148 | Jun 2005 | WO |
| WO 2005069840 | Aug 2005 | WO |
| WO 2005117756 | Dec 2005 | WO |
| WO 2005117953 | Dec 2005 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20080124764 A1 | May 2008 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60575175 | May 2004 | US | |
| 60605437 | Aug 2004 | US | |
| 60647925 | Jan 2005 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 11270864 | Nov 2005 | US |
| Child | 11998933 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 11136244 | May 2005 | US |
| Child | 11270864 | US | |
| Parent | 10999886 | Nov 2004 | US |
| Child | 11270864 | US |
